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Summary	  
Glioblastoma multiforme (GBM) are the most aggressive type of gliomas and lead to 
poor prognosis. Despite modern multimodal therapy, relapse recurs in up to 90% of 
all cases and the survival of patients is around one year in average. GBM are highly 
heterogenous at the genomic,  histopathological and disease progression level, which 
represents a great challenge for developing treatments. The aggressiveness and 
relapsing behavior of GBM partly relies on the presence of a population of cells with 
stem cell properties that are resistant to therapies and have the capacity to replenish 
the tumor bulk. These cancer stem cells (CSCs) share features with neural stem cells 
(NSCs) such as similar transcriptional regulatory pathways. In this study, we focused 
on the helix-loop-helix (i.e. ID proteins) and basic helix-loop-helix transcription 
factor network (i.e. E proteins and Olig2) to investigate its potential as target for 
therapeutic approaches. This transcriptional network regulates proliferation and 
differentiation of stem cells and is also involved in maintenance of tumor 
homeostasis. In this thesis, the aim was to disrupt the (b)HLH network in its ensemble 
with endogenous E proteins in order to induce anti-glioma effects. 
 
The first chapter describes how overexpression of a dominant-negative E protein 
(dnE47) lacking its nuclear localization signal in human glioblastoma-derived cells 
led to sequestration of HLH and bHLH proteins in the cytoplasm. DnE47 
overexpression induced apoptosis in adherent immortalized tumor cell lines and 
down-regulation of pro-proliferative as well as anti-apoptotic genes. Similar effects 
were detected in tumor-initiating cells derived from human GBM biopsies. In these 
later cells, overexpression of dnE47 impaired the sphere formation capacities of 
tumor-initiating cells and delayed the onset of clinical symptoms in a murine 
xenograft model.  
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Chapter two describes the development and establishment of tools and methods 
necessary for the study presented in Chapter one. We engineered an inducible 
lentiviral vector and established the optimal conditions for its application in patient-
derived tumor-initiating cells. We also present a more detailed histology of tumors 
induced in immunosuppressed mice as well as possible novel analytical approaches 
for characterizing the number and distribution of grafted cells within the mouse brain. 
In chapter three, we finally tested a novel xenograft model for assessing the ability of 
glioma-initiating cells to form tumors. We transplanted tumor-initiating cells in 
Drosophila melanogaster flies and monitored the survival, migration and tumor-
formation of the xenografts. 
 
To conclude, in this thesis I demonstrate the feasibility of using properties of 
endogenous proteins in order to disrupt a transcriptional network globally in the 
context of human glioblastoma and to achieve anti-glioma effects. 
  
	   8	  
Zusammenfassung	  
Glioblastoma multiforme (GBM) ist die aggressivste Art eines Glioms und ist mit 
einer geringen Überlebenschance assoziiert. Trotz multimodaler Therapie haben 
GBM Patienten eine Rückfallquote von bis zu 90% und überleben nach Diagnose 
durchschnittlich ein Jahr. GBM sind auf der genomischen, molekularen und 
histopathologischen Ebene sowie im Krankheitsverlauf extrem heterogen, was die 
Anpassung der Behandlung nötig, aber auch diffizil macht. Die Aggressivität und die 
hohe Rückfallquote von GBM sind teilweise auf die Präsenz einer Zellpopulation mit 
Stammzelleigenschaften zurückzuführen. Diese Zellen sind auf gewöhnliche 
Therapien resistent, da die überlebenden Stammzellen den Tumor wieder aufbauen 
können. Die physiologischen Eigenschaften von Krebsstammzellen und neuralen 
Stammzellen werden von gleichen molekularen Mechanismen reguliert, unter 
anderem vom Helix-loop-helix- (HLH) und Basic-Helix-loop-helix- (bHLH) 
Transkriptionsnetzwerk. In dieser Dissertation liegt der Focus sowohl auf HLH (i.e. 
ID Proteine) als auch auf bHLH (i.e. E Proteine und Olig2) Proteinen, um ihr 
Potential als neue therapeutische Zielmoleküle zu erforschen. Dieses Netzwerk von 
Transkriptionsfaktoren reguliert die Proliferation und Differenzierung von 
Stammzellen und ist auch bekannt dafür, die physiologischen Eigenschaften eines 
Tumors, wie zum Beispiel starke Proliferationsrate, Bildung neuer Blutgefässe und 
Invasion zu unterstützen. Das Ziel dieser Dissertation ist es, das gesamte HLH und 
bHLH Netzwerk mittels endogenen E Proteinen zum Erliegen zu bringen, um das 
Tumorwachstum zu unterbinden.  
 
Im ersten Kapitel wird gezeigt, wie die Überexpression eines dominant-negativen E 
Proteins (dnE47), das kein Kernlokalisationssignal hat, in von GBM abstammenden 
Zelllinien zu HLH und bHLH Sequestrierung im Zytoplasma fuhr. DnE47-
Überexpression verursachte den Zelltod von immortalisierten Gliomazelllinien und 
verringerte die Expression  von pro-proliferativen als auch von anti-apoptotischen 
Genen. Ähnliche Effekte wurden in Tumorstammzellen erzielt, die aus menschlichem 
GBM Gewebe isoliert wurden. DnE47-Überexpression in diesen Zellen 
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beeinträchtigte ihre Fähigkeit, Sphären zu bilden, und verzögerte das Auftreten von 
Krankheitssymptomen in einem Maus Xenotransplantationsmodell.  
 
Das zweite Kapitel beschreibt, wie die für die Studie vom ersten Kapitel nötigen 
Werkzeuge und Methoden etabliert wurden. Wir entwickelten induzierbare 
lentiviralen Vektoren und stellten den optimalen Rahmen her, um sie in 
Tumorstammzellen von Patienten anzuwenden. Wir stellen auch eine ausführlichere 
Histologie von Tumoren vor, die in immunsupprimierten Mäusen induziert wurden, 
sowie mögliche neue analytische Methoden für die Charakterisierung von Anzahl und 
Verteilung transplantierter Zellen innerhalb des Mausgehirns.  
 
Im dritten Kapitel testeten wir ein neues Xenotransplantatmodell für Tumorbildung. 
In diesem Experiment wurden menschliche Krebsstammzellen in Drosophila 
melanogaster Fliegen transplantiert und das Verhalten des Transplantats und das 
Tumorwachstum beobachtet. 
 
In dieser Dissertation beweise ich, dass Eigenschaften von endogenen Proteinen 
benutzt werden können, um ein Transkriptionsnetzwerk im Kontext von 
Glioblastomen global zum Erliegen zu bringen und dadurch gegen den Tumor zu 
wirken. 
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Chapter	  I	  
 
 
 
Introduction	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Introduction	  
1.	  Glioblastoma	  multiforme	  
1.1	  Clinical	  prognosis	  and	  standard	  therapy	  
	  
Gliomas are the most aggressive and common primary brain tumors. Approximately 
3-4 cases per 100’000 people are diagnosed each year worldwide and the median 
survival rate is of 3 months without treatment (Ohgaki & Kleihues 2005; Parkin & 
Muir 1992; Chaudhry et al. 2013). These aggressive tumors generally occur in elderly 
patients over 60 and actual standard treatments are adapted to the age of the patient 
(Chaudhry et al. 2013). Treating brain tumors typically involves surgical resection, 
followed by radiotherapy, which already significantly improves the median survival 
of patients (Walker et al. 1980; Laperriere et al. 2002). Adjuvant chemotherapy with 
nitrosourea-based drugs or oral administration of Temozolomide (TMZ), an atypical 
alkylating agent, increases the median survival of patients (Stewart 2002; Stupp et al. 
2005; Stupp et al. 2009). More specifically, the combination of radiations and TMZ 
treatment was shown to significantly improve survival (Stupp et al. 2005). However, 
despite combining radiotherapy and chemotherapy, tumors recur in 90% of the cases 
with a more aggressive phenotype and to this day, no existing cure can offer survival 
on the long-term (Brada et al. 2001; Stupp et al. 2009).  
1.2	  Classifications	  
	  
Primary brain tumors were originally named gliomas according to the neural cell type 
they share features mostly with: glial cells. Based on histopathology, 
immunohistochemistry and ultrastructural analyses, gliomas are classified as 
astrocytomas and oligendrogliomas or oligoastrocytomas if showing a mixed 
astrocytic and oligodendrocytic signature (Furnari et al. 2007; Westphal & Lamszus 
2011). Primary brain tumors are further distinguished depending on their 
aggressiveness according to a scale developed by the World Health Organization 
(WHO), grouping tumors into four grades: I to IV (Louis et al. 2007). 
Oligodendroglioma and oligoastrocytoma can range from grade II to III, astrocytomas 
from grade I to IV and the most aggressive types of tumor are astrocytomas grade IV, 
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also known as glioblastoma multiforme (Louis 2006). Glioblastoma multiforme 
(GBM) are malignant tumors with poor prognosis and a median survival of about 14 
months (Stupp et al. 2005). High-grade tumors (grade III-IV) are characterized by 
rapidly proliferating cells, a dense vasculature and are highly anaplastic whereas low-
grade tumors (grade I-II) divide slowly and show a high cell density with a more 
differentiated histology (Miller & Perry 2007; Riemenschneider & Reifenberger 
2009). Low-grade tumors generally occur in patients younger than 45 years old 
whereas high-grade glioblastoma are predominantly diagnosed in elder patients 
(Furnari et al. 2007). Interestingly, lower-grade tumors grow diffusely throughout the 
brain without affecting normal functions whereas high-grade tumors are more rapidly 
fatal (Furnari et al. 2007; Westphal & Lamszus 2011). GBM can either appear de 
novo (therefore called primary tumors) or evolve from lower grade astrocytomas and 
form secondary tumors. This progression from low to high grade occurs through 
oncogenic molecular events, thereby generating genetic alterations leading to a more 
aggressive and metastatic phenotype (Westphal & Lamszus 2011). Although primary 
and secondary tumors share similar histopathological features, their genomic profiles 
show striking differences. This heterogeneity challenges therapeutic approaches even 
more as tumors will not react in the same manner to different therapies (Maher et al. 
2006; Furnari et al. 2007). 
1.3	  Histological	  and	  molecular	  heterogeneity	  
	  
Each GBM is unique in its histopathology, genomic profile and time course, which 
accounts for a high inter- and intra-tumor heterogeneity. This makes it difficult for 
clinicians to adapt therapies for each individual for optimization of survival and life 
quality (Chaudhry et al. 2013). Hopes to develop more personalized treatments rely 
on a more accurate classification and correlation between phenotype and prognosis in 
order to discover markers that predict the survival of patients. Hence, scientists have 
been aiming at developing new classifications based on genomic analyses in order to 
better understand GBM and improve health care (Phillips et al. 2006; Maher et al. 
2006; Verhaak et al. 2010). In these studies, transcriptome analyses combined with 
cohort patient history and histology revealed recurrent mutations present in GBM 
tumors showing phenotypic similarities. For example, amplifications of epidermal 
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growth factor receptor (EGFR) and loss of phosphatase and tensin homolog (PTEN) 
loci leading to a highly proliferative behavior of tumor cells correlate  
with poor prognosis whereas tumors showing neuronal features respond better to 
therapy (Phillips et al. 2006; Maher et al. 2006; Verhaak et al. 2010). In 2010, a study 
based on The Cancer Genome Atlas (TCGA) database introduced a new classification 
model with four molecular subclasses of GBM. Proneural, neural, classical and 
mesenchymal subtypes were distinguished along alterations in EGFR, neurofibromin 
1 (NF1), platelet-derived growth factor receptor alpha/isocitrate dehydrogenase 1 
(PDGFRα/IDH1) and neuronal markers such as neurofilament light chain (NFL) or 
gamma-aminobutyric acid (GABA) A receptor alpha subunit 1 (GABRA1), 
respectively. Here as well, responses to therapy correlated with the different subtypes, 
proneural tumors showing poor and classical tumors good responses (Verhaak et al. 
2010). Individualization of therapy is not only challenged by the heterogeneity 
between tumors but also by heterogeneity within the tumor itself (Swanton 2012). In 
fact, genomic profiles of biopsies obtained from different areas of a single tumor 
showed diverse fingerprints, underlining the presence of different subtypes of cell 
populations (Liang et al. 2005; Sottoriva et al. 2013). Furthermore, this intra-tumor 
heterogeneity evolves over time, which might partially explain the variability in 
response to therapy (Sottoriva et al. 2013). In conclusion, the correlation between 
tumor heterogeneity and the clinical outcome still needs to be further investigated in 
order to better understand the pathology of brain tumors and optimize therapeutic 
approaches accordingly.  
	   14	  
2.	  The	  origin	  of	  glioblastoma	  multiforme	  
More precise knowledge of tumor characteristics relies on unraveling where and how 
tumors arise. One of the biggest controversies in this field of research concerns the 
origin of primary brain tumors. In the last decade, three possibilities for cell-of-origin 
were suggested. First, tumors might occur through dedifferentiation of non-dividing 
mature neural cells. Second, slowly dividing neural progenitor cells might give rise to 
tumors. Finally, the existing pool of neural stem cells in the adult brain offers a 
plausible explanation for the origin of gliomas. In the following paragraphs, I will 
describe these three different hypotheses and discuss data supporting them in more 
details.  
2.1	  Dedifferentiating	  post-­‐mitotic	  neural	  cells	  
	  
The adult human brain is made of approximately a 100 billion of neurons and ten to 
fifty times more glial cells, the vast majority of which are in a post-mitotic state. The 
possibility that tumors arise from these cell populations implies their dedifferentiation 
into a less mature state (Bachoo et al. 2002; Moon et al. 2011; Friedmann-Morvinski 
et al. 2012). In the healthy postnatal brain, astrocytes have been shown to 
dedifferentiate into neurons after overexpression of pro-neural genes such as Pax6, 
Neurogenin2 (Ngn2) or murine acyl-CoA synthetase long-chain family member 1 
(Mash1), revealing a more plastic potential than previously thought (Heins et al. 
2002; Berninger et al. 2007). Similarly, by silencing both tumor suppressor genes 
NF1 and p53 in either glial fibrillary acidic protein (GFAP)-expressing glial or 
Synapsin I-expressing neuronal cells, formation of tumors was induced in mice 
(Friedmann-Morvinski et al. 2012). Also, the embryonic marker Nanog was shown to 
induce dedifferentiation of astrocytes in the absence of p53, leading to the formation 
of cancer stem-like cells (Moon et al. 2011). Finally, it was demonstrated that in the 
absence of both tumor suppressor genes p16Ink4a and p19Arf, astrocytes dedifferentiate 
upon EGFR activation and form high-grade gliomas (Bachoo et al. 2002). However, 
despite the possibility that post-mitotic neural cells show the potential to 
dedifferentiate, this process still remains unlikely as it implies two steps: first, a de-
differentiation of the mature cell and second, the transformation of the de-
differentiated cell. Thus, although the experiments discussed above represent proof-
of-principle that post-mitotic neural cells can generate tumors, these cells are not 
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favored as the cells of origin of tumors (Westphal & Lamszus 2011). The existence of 
neural progenitor cells which show a proliferative behavior represents a more 
plausible source of origin for tumors.  
2.2	  Gliomas	  from	  neural	  progenitor	  cells	  
	  
Neural progenitors such as oligodendrocytes progenitor cells (OPCs) or neural stem 
cells are present in the adult mammalian brain, have the ability to proliferate and were 
shown to induce tumors after the occurrence of oncogenic events such as mutations or 
copy-number alterations (Levine et al. 2001; Alvarez-Buylla & Lim 2004; Persson et 
al. 2010; Liu et al. 2011). OPCs are present throughout the central nervous system 
(CNS), proliferate constantly and respond to injury by increasing their proliferation 
(Levine et al. 1993; Dawson et al. 2000; Horner et al. 2000; Levine et al. 2001; 
Barnabé-Heider et al. 2010). Similar to astrocytes, the potential of OPCs in the adult 
brain is not fully restricted to an oligodendrocytic fate since they are able to 
dedifferentiate into multipotent progenitors and re-differentiate into neurons in vitro 
and in vivo (Kondo 2000; Belachew et al. 2003; Nunes et al. 2003). Using a mosaic 
analysis with double markers (MADM) approach, OPCs were shown to grow 
aberrantly and to form tumors when NF1 and p53 were mutated. The contribution of 
OPCs to tumor formation was also observed when the mutations were introduced in 
neural stem cells, indicating that the oligodendroglial lineage is the most permissive 
to transformation (Liu et al. 2011). Based on a transgenic murine glioma model in 
which p53 was deleted concomitantly with EGFR activation under the control of the 
S100beta promoter, OPCs were suggested to be at the origin of oligodendrogliomas. 
These tumors showed an enrichment of OPC markers such as Sox10, PDGFRα or 
NG2 both in mouse and human oligodendroglioma (Weiss et al. 2003; Persson et al. 
2010). These findings imply that progenitor cells, in particular those from the 
oligodendroglial lineage, retain the potential to proliferate and are highly sensitive to 
oncogenic molecular events. Besides lineage specific progenitors, neural stem cells 
are believed to be present in particular regions of the adult CNS and may participate 
to tumor formation as well.  
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2.3	  Adult	  neural	  stem	  cells	  as	  the	  origin	  of	  tumors	  
	  
In the adult human brain neural stem cells proliferate constantly, self-renew their pool 
and are able to give rise to both glial cells and neurons (Eriksson et al. 1998). They 
are present in the two neurogenic niches of the adult mammalian brain: the dentate 
gyrus of the hippocampus and the subventricular zone (Alvarez-Buylla & Lim 2004). 
In the context of cancer, a subpopulation of GFAP positive neural stem cells 
expressing PDGFRα and located within the walls lining ventricles were shown to 
overproliferate and to form glioma-like hyperplasias upon PDGF infusion (Jackson et 
al. 2006).  Similarly, overexpression of Akt and Ras, two genes known to be highly 
active in GBM, in Nestin+ stem cells induced gliomas in a murine tumor model 
(Holland et al. 2000; Cheng et al. 2009; Feldkamp et al. 1997). On the other hand, 
heterozygous deletion of tumor suppressor genes Nf1, p53 and Pten in Nestin+ 
stem/progenitor cells lead to the formation of malignant astrocytomas (Alcantara 
Llaguno et al. 2009). These findings suggest that germinal zones of the adult CNS 
constitute environments potentially favorable for oncogenic events and that these 
initial transformation steps preferentially occur in non-committed cells such as NSCs 
rather than in their progeny: i.e. astrocytes or oligodendrocyte precursor cells. 
Unraveling the true origin of brain tumors will contribute to better understand their 
physiology and develop cell-specific therapies. 
 
3.	  The	  cancer	  stem	  cell	  theory	  
Although the identity of the cell-of-origin for brain tumors remains to be fully 
determined, tumors themselves are known to contain populations of stem cells that 
build up and replenish the bulk of the tumor (Stiles & Rowitch 2008). The 
terminology is still under debate with a lack of clear definitions. For this reason, it is 
important to make the difference between a cancer stem cell (CSC) as the cell in 
which the original oncogenic events occurred and a CSC as a cell able to give rise to 
the different type of cells constituting the tumor (Valent et al. 2012).   
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3.1	  Cancer	  stem	  cells	  
	  
In 2003, a new area of research arose when Singh and colleagues isolated a cell 
population able to proliferate, self-renew and differentiate in vitro from human 
pediatric brain tumors (Singh et al. 2003). The purification was based on the cell 
surface marker CD133 (also known as Prominin-1, a transmembrane glycoprotein) 
which is also expressed on the surface of adult neural stem cells (Obermair et al. 
2010; Beckervordersandforth et al. 2010). In vivo xenografts of these CD133 positive 
cells (but not CD133 negative cells) led to the formation of tumors that could be 
serially transplanted and which phenocopied the histopathology of the patient’s tumor 
(Singh et al. 2004). The presence of this cancer stem-like cell population was 
confirmed in GBM (Yuan et al. 2004). CD133 positive cells are characterized by the 
expression of other neural stem cell markers such as Nestin and Sox2 (Lendahl et al. 
1990; Komitova & Eriksson 2004). However, the relevance of this marker for CSC 
identification was questioned when CD133 negative cancer cells were shown to be 
able to form tumors as well (Nishide et al. 2009). The folding of the CD133 surface 
marker is glycosylation-dependent and might influence its detection as it is present on 
both CSCs and differentiated tumor cells (Kemper et al. 2010). These controversial 
findings might also be due to technical issues, different isolation methods showing 
diverse CD133 purification levels (Clément et al. 2009). Therefore, additional surface 
markers such as transmembrane glycoprotein CD44, or the adhesion molecule CD15 
(also called LewisX or stage-specific embryonic antigen 1 (SSEA-1)) are needed for a 
more stringent detection and isolation of CSCs (T.-A. Read et al. 2009; Son et al. 
2009; Anido et al. 2010). Another alternative would be to isolate CSCs without 
relying on markers based on autofluorescence properties and morphology (Clément et 
al. 2010). All in all, there is a need for more specific markers for CSC detection, as it 
will help revealing the cell-of-origin of the tumor and ultimately lead to the 
development of more specific therapeutic approaches.  
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Adaptation of therapies has to be considered as CSCs have the ability to resist to 
current treatments such as radiations and chemotherapy. Their resistance to 
radiotherapy is due to their increased DNA repair capacity and to chemotherapeutic 
agents such as Temozolomide (TMZ) thanks to the detoxifying protein O6-
methylguanine-DNA-methyltransferase (MGMT) (Bao et al. 2006; Eramo et al. 2006; 
Beier et al. 2008). Highlighting this resistant phenotype, a small sub-population of 
CSCs within tumors was shown to be the cause for tumor reappearance after 
temozolomide (TMZ) treatment in a genetic glioma mouse model (Chen et al. 2012). 
Additionally, resistance to therapy might be influenced by other extrinsic factors such 
as tumor niche factors, the hypoxic environment or the reacquisition of stem cells 
features by non-stem cells (Beier et al. 2011). Since more CD133+ cells appear under 
hypoxic conditions, CSCs or non-CSCs seem to be able to adapt to the environment 
(Griguer et al. 2008; Soeda et al. 2009). Thus, CD133 might be more representative 
for a transient state of stem cells within a tumor than an absolute detecting marker, 
further highlighting the necessity to better characterize the expression markers and 
physiology of CSCs (Griguer et al. 2008).    
3.2	  Cancer	  stem	  cells	  and	  neural	  stem	  cells	  
	  
Since brain cancer stem cells and neural stem cells share common properties such as 
self-renewal, proliferation and differentiation into neural lineages, it has been 
suggested that common regulatory pathways control the physiology of both cell types. 
Confirming this hypothesis, evidences show that canonical developmental signaling 
pathways such as NOTCH and Wnt are implicated in glioblastoma as well (Pierfelice 
et al. 2008; Gong & Huang 2012). In addition to common regulatory pathways, these 
cells also share the ability to migrate throughout the brain: neural stem cells (NSCs) 
migrate during development through cortical layers to reach their final location and 
CSCs spread along white matter tracts to invade all brain regions (Cayre et al. 2009; 
Westphal & Lamszus 2011). This migratory phenotype is seen as well when NSCs are 
attracted to the site of tumor, where both populations can interact (Aboody et al. 
2000; Mapara et al. 2007). Additionally, CSCs and NSCs were suggested to be related 
at the molecular level and to share similar transcriptional profiles (Taylor et al. 2005; 
Sharma et al. 2007). However, although they share common stem- and lineage 
characteristic markers, genome-wide studies revealed a greater heterogeneity in the 
transcriptome of CSCs showing a deregulated Wnt pathway when compared with 
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NSCs (Sandberg et al. 2013). Nevertheless, knowledge acquired from NSCs can be 
transposed to CSCs in order to better understand the neurobiology of gliomas since 
similar pathways are involved in the physiology and behavior of both cell 
populations. 
 
4.	  (basic)	  helix-­‐loop-­‐helix	  transcription	  factors	  
	  
4.1	  (basic)	  helix-­‐loop-­‐helix	  transcription	  factors	  in	  the	  healthy	  brain	  
	  
Helix-loop-helix (HLH) and basic helix-loop-helix (bHLH) proteins are transcription 
factors involved in stem cell homeostasis during development as well as later on in 
the postnatal brain (Massari & Murre 2000; Jones 2004). According to Murre’s 
classification system, the four E proteins (E47, E12, E2-2- and HEB) constitute Class 
I; whereas Class II regroups tissue-specific bHLH proteins responsible for 
differentiation such as Olig proteins. Class I proteins form homo- or heterodimers 
with Class II proteins in order to transactivate transcription of target genes through E-
box sequence recognition in many tissues (Murre, McCaw & Baltimore 1989; 
Massari & Murre 2000). Class IV encloses the four ID proteins (1-4) which lack a 
DNA binding domain, can dimerize with Class I and II and therefore negatively 
regulate transcription (Murre et al. 1994; Massari & Murre 2000). ID proteins show 
no preferential binding affinity with E proteins, suggesting interchangeable 
dimerization properties (Massari & Murre 2000; Teachenor et al. 2012). BHLH and 
HLH proteins are involved in the development, proliferation, differentiation and 
maintenance of neural stem cell during development and in the adult neurogenic 
niches (Lee 1997; Ruzinova & Benezra 2003; Niola et al. 2012).   
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4.2	  (basic)	  helix-­‐loop-­‐helix	  transcription	  factors	  in	  cancer	  
	  
Both bHLH and HLH are implicated in tumor homeostasis. BHLH proteins such as 
Olig1, Olig2 and Ascl1 are expressed in different types of glioma and have been 
shown to be involved in the maintenance of a proliferative state as well as in the 
formation of tumors (Aguirre-Cruz et al. 2004; Ligon et al. 2004; Somasundaram et 
al. 2005; Ligon et al. 2007).  Especially Olig2 has been investigated in the context of 
cancer. Olig2 antagonizes the action of the tumor suppressor p53 by interfering with 
its post-translational modification and therefore rendering cells resistant to toxic 
damage (Mehta et al. 2011). Olig2 has a differential action depending on its 
phosphorylation state since it supports a proliferative behavior only when 
phosphorylated (Ligon et al. 2007; Li et al. 2011; Sun et al. 2011). This 
phosphorylated state appears to be a characteristic of high-grade tumors whereas low-
grade tumors rather express unphosphorylated Olig2 (Mehta et al. 2011).  
 
Besides bHLH proteins, ID proteins are also involved in tumor homeostasis by 
playing diverse and important roles in angiogenesis, proliferation and migration of 
cancer cells (Lyden et al. 1999; Coma et al. 2010; Paolella et al. 2011; O’Brien et al. 
2012). In absence of ID proteins, angiogenis is impaired during development as well 
as the neovascularization of tumors (Lyden et al. 1999). HLH proteins were suggested 
to sustain a highly proliferative state by interacting with the p16Ink4a/Rb pathway 
(Lasorella et al. 2000; Ouyang et al. 2002). Finally, repression of Semaphorin 3F 
through ID2 implicates that these proteins support of migratory behavior as well 
(Coma et al. 2010). Because of all their roles in sustaining tumor homeostasis, ID 
proteins became attractive targets for designing novel therapeutic approaches 
(Ciarapica et al. 2009; Demissew S Mern et al. 2010; Mellick et al. 2010; Trabosh et 
al. 2009).  
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Finally, E proteins seem to be involved in the regulation of proliferation, cell death 
and cell adhesion as well. Overexpression of E12 or E47 in the absence of E2A 
induced cell death in murine lymphoma cell lines, suggesting a tumor suppressive role 
for E2A proteins (Engel & Murre 1999b). In fibroblasts, E47 overexpression and ID 
neutralization suppresses proliferation (Peverali et al. 1994). Confirming the anti-
proliferative action of E proteins, E12 and E47 were shown to induce the transcription 
of cyclin-dependent kinase inhibitors p27KIP1 in the absence of ID2 (Trabosh et al. 
2009). Cell-cycle progression was reported to be impaired after E47 overexpression in 
the context of pancreatic ductal adenocarcinoma (Lee et al. 2011). Lastly, E47 was 
also shown to be involved in the epithelial-mesenchymal transition (EMT) of 
epithelial cells by repressing E-cadherin expression (Perez-Moreno et al. 2001). It is 
still unclear whether these effects are mediated directly by E proteins or by their 
dimerization with ID and/or other bHLH proteins. Therefore, further investigation is 
needed before considering these transcription factors as potential anti-glioma targets, 
as described in this thesis.  
 
Since both HLH and bHLH sustain hallmarks of tumor homeostasis such as 
proliferation, neovascularization and migration, they appear as potential targets for 
the development of novel therapeutic approaches. Furthermore, the ability of E 
proteins to interact with the entire ensemble of HLH and bHLH proteins highlight 
their potential as tool for global targeting of this transcriptional network.  
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5.	  Therapeutic	  approaches	  
	  
5.1	  Individualized	  therapies	  
	  
It has been known for a long time already that drug sensitivity correlates with 
pathway alterations in human glioma cell lines (Weller 1998). Hence, large-cohort 
clinical studies have been aiming at solving the question of correlation between the 
molecular expression profiles of tumors and the patients’ response to therapy. A 
recent finding showed that promoter methylation of the MGMT gene correlates with a 
longer survival and a better response to TMZ treatment than radiotherapy (Wick et al. 
2012). On the other hand, TP53 mutations and CDKN2A deletions were found to 
correlate with resistance to radiotherapy and poor survival prognosis (Shih et al. 
2005). These findings underline the fact that patients with different tumor profiles will 
respond differentially to various treatment modes and that there is a need for 
individualized therapies. 
5.2	  Disruption	  of	  transcription	  factor	  networks	  as	  a	  therapeutic	  goal	  
	  
Since tumor formation and maintenance rely on mutations and alterations of different 
signaling and transcriptional pathways, scientists have been aiming at modulating or 
interfering with them with the hope to disrupt tumor cell homeostasis. A lot of efforts 
have been put into finding out ways to interfere at the level of transcription or at the 
level of protein-interaction (Zhou et al. 2009; Yan & Higgins 2013; Ivanov et al. 
2013). Developmental regulatory pathways such as the Sonic Hedgehog (Shh), 
NOTCH or Wnt pathways are such prominent targets for glioblastoma therapy and 
small inhibitor molecules or antibodies have already been identified (Zhou et al. 
2009). NOTCH signaling blockade provoked cancer stem cell depletion and apoptosis 
in embryonal brain tumors (Fan et al. 2006). Alternatively, differentiation was 
obtained by activation of the Wnt pathway in GBM-derived cells in a hypoxic 
environment, leading to a less oncogenic phenotype (Rampazzo et al. 2013). The 
HLH/bHLH transcription factor family accounts for attractive therapeutic targets as 
well, especially ID proteins (Iavarone & Lasorella 2006). One successful approach 
was to induce cell death and differentiation in glioma stem-like cells by 
overexpressing neurogenic transcription factors such as Ngn2 or NeuroD1 (Guichet et 
al. 2012). Using peptides specifically interfering with ID protein interactions, 
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differentiation, cell death and cell cycle arrest were induced in vitro (Ciarapica et al. 
2009; Demissew S Mern et al. 2010; D S Mern et al. 2010a). These findings highlight 
the potential of transcription factors as both targets and means for therapeutic 
approaches (Yan & Higgins 2013). Nevertheless, developing new therapeutic tools 
also implies the development of efficient and specific delivery.  
5.3	  Delivery	  tools:	  from	  nanoparticles	  to	  cellular	  vehicles	  
	  
Treating brain tumors is challenging since the central nervous system is protected by 
the blood-brain-barrier, thereby preventing the entry of most drugs and 
chemotherapeutic agents (Pardridge 2005; de Vries et al. 2006). Furthermore, the 
brain is an organ in which cells are mostly differentiated or have a very slow turnover, 
which has implications for recovery after surgical resections (Westphal & Lamszus 
2011). The challenge is therefore to combine knowledge from oncology and 
neurobiology in order to deliver an individualized treatment specifically and 
efficiently to the site of the tumor or even to a subpopulation of cells whilst 
minimizing any toxic events that would lead to dramatic consequences in the healthy 
neighboring tissue. 
 
The emergence of nanomedicine led to the discovery of new ways to deliver small 
compounds to tumor sites. Both organic and inorganic nanoparticles have the 
potential of a better blood-brain-barrier penetration and can be engineered to 
selectively target the cell of interest based on their affinity for specific antibodies or 
ligands (Liu et al. 2007). Additionally, they could be used not only for therapeutic 
purposes but also as imaging tools for diagnosis, for example with fluorescently 
labeled particles (Liu et al. 2007; del Burgo et al. 2013). A successful application of 
nanovesicles as therapeutic tools was achieved by efficiently disrupting angiogenesis 
in glioblastoma (Wojton et al. 2013). Coupled to nanoparticles, small peptides offer 
the possibility to target tumor cells based on receptor affinity, internalization and 
cleavage of the peptide (Teesalu et al. 2009; Alberici et al. 2012). Alternatively, based 
on recent progress in viral therapy, targeting tumor cells is also possible with viruses. 
For example, using a modified oncolytic measle virus to target human CD133+ 
glioblastoma cells selectively killed this subpopulation of cells both in vitro and in 
vivo (Bach et al. 2013). Finally, since endogenous and transplanted stem cells were 
shown to migrate to the site of tumor, their potential as drug delivery units has been 
	   24	  
investigated as well (Aboody et al. 2000; Benedetti et al. 2000; Uhl et al. 2005; 
Aboody et al. 2008). Unfortunately, these innovative approaches are not clinically 
applicable yet, and new findings should therefore be considered cautiously. In 
conclusion, further investigations of the potential of nanoparticles, peptides, 
therapeutic viruses and stem cells as carriage tools will lead to optimization of 
targeted treatment delivery. 
5.4	  Single	  vs.	  combined	  vs.	  global	  approaches	  
	  
Considering the large inter- and intra-heterogeneity in tumors and the number of 
molecular pathways involved in oncogenic events, therapeutic approaches targeting a 
single component or aspect do not offer a cure for tumors on the long term. Currently, 
radiotherapy or chemotherapy which attack the tumor sites broadly still are the 
standard and most efficient treatments for brain cancer (Stupp et al. 2009). Yet, the 
numerous side effects including damaging the healthy tissue, resistance and mutation 
of cancer cells as well as a poor quality of life highlight the lack of optimal 
therapeutic approaches. There is a need for wide-range approaches but in a specific 
context, meaning the targeting of cancer cells without provoking any collateral 
damages. The answer might lie in predictive identification of key nodes in cancer 
pathways by metabolomics for example (Tang et al. 2013; Aboud & Weiss 2013; 
Gupta & Chawla 2013). Following this larger approach, polypharmacology is a new 
field for drug discovery, for example aiming at finding broad tropism kinase 
inhibitors (Knight et al. 2010; Rehemtulla 2012; Tang & Aittokallio 2013). The same 
logic might apply to transcription factor networks. The identification of 
transcriptional hubs or nodes critical for tumor physiology have the potential to reveal 
targets that are essential for supporting multiple aspects of tumorigenesis.  
 
To conclude, combining knowledge from transcriptional networks sustaining tumor 
homeostasis, with delivery tool engineering is necessary to develop more efficient and 
personalized cancer therapies in the future.  
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6.	  Aims	  of	  the	  thesis	  	  
 
Based on the central role of HLH/bHLH proteins in controlling the physiology of 
neural stem cells and cancer stem cells, the aims of my thesis were as follows: 
1) Manipulate E proteins in order to interfere with the natural activity of 
HLH/bHLH networks in GBM cells and investigate the consequences of these 
manipulations 
2) Test a mutated form of E proteins that could disrupt more efficiently 
HLH/bHLH networks in GBM cells 
3) Explore the potential of this approach in GBM-initiating stem cells  
Globally, the aim of the thesis was to use properties of endogenous proteins in order 
to achieve anti-glioma effects by targeting a transcriptional network in its ensemble. 
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Chapter	  2	  
 
 
 
Targeting	  the	  bHLH	  transcriptional	  
networks	  by	  mutated	  E	  proteins	  in	  
experimental	  glioma	  
 
 
(under review) 
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Abstract	  
	  
Glioblastomas (GB) are aggressive primary brain tumors. Helix-loop-helix (HLH, ID 
proteins) and basic HLH (bHLH, e.g. Olig2) proteins are transcription factors that 
regulate stem cell proliferation and differentiation throughout development and into 
adulthood. Their convergence on many oncogenic signaling pathways combined with 
the observation that their overexpression in GB correlates with poor clinical outcome 
identifies these transcription factors as promising therapeutic targets. Important 
dimerization partners of HLH/bHLH proteins are E proteins that are necessary for 
nuclear translocation and DNA binding. Here, we overexpressed a wildtype or a 
dominant negative form of E47 (dnE47) that lacks its nuclear localization signal thus 
preventing nuclear translocation of bHLH proteins in long-term glioma cell lines and 
in patient-derived glioma-initiating cell lines and analyzed the effects in vitro and in 
vivo. Whilst overexpression of E47 was sufficient to induce apoptosis in absence of 
bHLH proteins, dnE47 was necessary to prevent nuclear translocation of Olig2 and to 
achieve similar pro-apoptotic responses. Transcriptional analyses revealed down-
regulation of the anti-apoptotic gene BCL2L1 and the pro-proliferative gene CDC25A 
as underlying mechanisms. Overexpression of dnE47 in patient-derived glioma-
initiating cell lines with high HLH and bHLH protein levels reduced sphere formation 
capacities and expression levels of Nestin, BCL2L1 and CDC25A. Finally, the in vivo 
induction of dnE47 expression in established xenografts prolonged survival. In 
conclusion, our data introduce a novel approach to jointly neutralize HLH and bHLH 
transcriptional networks activities, and identify these transcription factors as potential 
targets in glioma. 
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Introduction	  
	  
Glioblastoma (GB) are aggressive primary brain tumours. Despite therapeutic 
interventions including surgical resection, radiation therapy and temozolomide 
chemotherapy, the median overall survival is only in the range of 15-16 months even 
in selected clinical trial populations (Stupp et al. 2009; Gilbert et al. 2011).  
Recently, a link between neural stem/glial progenitor cells and tumour cells in the 
central nervous system has been suggested (Jackson et al. 2006; Tabatabai & Weller 
2011). Indeed, brain tumours comprise a population of stem cells that are resistant to 
therapy and may thus contribute to relapsing cancer following treatment (Germano et 
al. 2010; Tabatabai & Weller 2011). This phylogeny suggests similarities in the 
molecular control of neural stem and glioma cells and provides opportunities to 
identify key transcriptional networks involved in GB pathogenesis.  
The regulatory networks controlling stem cell behaviour in the vertebrate brain are 
well characterized. Helix-loop-helix (HLH) and basic helix-loop-helix (bHLH) 
transcription factors play a central role in both normal and pathologic cell 
proliferation. These transcription factors (TFs) can be categorized in subclasses based 
on their structure and transcriptional activity (Murre’s classification; (Massari & 
Murre 2000)). Class I bHLH proteins, i.e. E proteins consisting of E2-2, E2A and its 
two splicing variants E12 and E47, as well as HEB, are ubiquitously present in 
embryonic as well as adult stem cells. These TFs act by homo or hetero-dimerizing 
with tissue-specific bHLH proteins (Class II), in order to facilitate their nuclear 
translocation and binding to E-box elements in promoter regions of target genes 
(Massari & Murre 2000). Inhibitors of DNA-binding or differentiation proteins (ID1-
4) belong to Class V. ID1-4 lack the basic DNA binding domain and form inactive 
heterodimers with Class I and Class II proteins, thereby acting as negative regulators 
of bHLH transcription factors activity by actively preventing their DNA binding 
(Benezra et al. 1990). 
Interestingly, Class V proteins are over-expressed in a wide range of human tumors, 
including GB (Hasskarl & Munger 2002). Four essential hallmarks of malignancy are 
conferred by dysregulated expression of ID proteins during tumourigenesis: anaplasia, 
uncontrolled proliferation, sustained neo-angiogenesis and invasion of neighbouring 
tissues (Lasorella et al. 2001). ID proteins may act in cancer cells by: i) sequestering 
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E proteins, ii) interaction with non-bHLH proteins such as pocket proteins of the 
retinoblastoma family, E-twenty six (ETS) or Paired-Box (Pax) proteins (Ruzinova & 
Benezra 2003). In addition to ID proteins, malignant gliomas of WHO grades II-IV 
express the class II bHLH protein Olig2 (Ligon et al. 2004) which is required for 
glioma formation in a genetically relevant murine model (Ligon et al. 2007). Notably, 
Olig2 expression is correlated with poor outcome in human gliomas (Ligon et al. 
2004; Lu et al. 2001).  
Although HLH and bHLH proteins (thereafter jointly defined as (b)HLH proteins) 
have been proposed as potential therapeutic targets (Fong et al. 2004; Ciarapica et al. 
2009; Demissew S Mern et al. 2010), single gene approaches are prone to lead to 
acquired escape mechanisms. This is particularly true for bHLH proteins that show 
heterogeneous expression levels among tumour classes and highly dynamic regulation 
among tumour cell types. Moreover, the transcriptional nature and nuclear location of 
these proteins hampers their efficient targeting for therapeutic intervention (Yan & 
Higgins 2013; Henke et al. 2008). The dynamic interactions and inter-dependence of 
(b)HLH protein classes to fine tune transcriptional activity however give rise to a 
unique opportunity to develop such a strategy. In particular, E protein might represent 
a prime target to neutralize (b)HLH transcriptional networks activity as a whole. E 
proteins bind Class II and V proteins with high affinity (Massari & Murre 2000; 
Teachenor et al. 2012; Samanta & Kessler 2004; Geoffroy et al. 2009) to regulate 
their sub-cellular localization and DNA binding. Moreover, subtle changes in their 
expression levels critically impact their function in regulating gene expression and 
cellular function (Dorshkind 1994). 
Here, we used overexpression of wild-type or mutated E proteins to induce cell cycle 
arrest and death in glioma cells. We demonstrate that overexpression of a dominant-
negative form of E47 lacking its nuclear localization signal, allows co-targeting of 
class II and V (b)HLH proteins and represents a novel potent anti-glioma strategy. 
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Material	  and	  Methods	  
	  
Cell lines and Culture 
The human glioma cell lines LN-308 and LNT-229 (Wischhusen et al. 2003) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Life Technologies, Carlsbad, CA, USA), 
supplemented with 10% fetal bovine serum (Invitrogen, Life Technologies, Carlsbad, CA, USA) and 
1% antibiotic-antimycotic 100x (Gibco). Cells were split every 3-4 days using 0.25% Trypsin-EDTA 
(Gibco). Glioma-initiating cell lines (S24, T269 and T325) (Rieger et al., 2008) were cultured in 
DMEM:F12 (Gibco) supplemented with 2% B-27 minus Vitamin A (Gibco), 1% antibiotic-antimycotic 
100x (Gibco), human leukemia inhibitory factor 20ng/ml (Millipore, Merck, Billerica, MA, USA), 
Heparin 5ug/ml (STEMCELL Technologies, Vancouver, BC, Canada), recombinant human fibroblast 
growth factor 20ng/ml (Peprotech, Hamburg, Germany) and epidermal growth factor 20ng/ml. Cells 
were maintained at clonal densities (10 cells/µl) in T75 culture flasks (TPP, Trasadingen, Switzerland) 
and passaged weekly using Accutase (Chemie Brunschwig AG, Basel, Switzerland) for dissociation. 
Cell transfection  
The generation of E47-RFP and dnE47-RFP constructs has been described elsewhere (Mehmood et al. 
2009). As a control plasmid we used a pCAGGS_IRES_NLS_GFP vector. Cells were transfected by 
using both nucleofection and lipofectamin, as described below. 
LNT-229 and LN-308 cells were nucleofected using the Amaxa Nucleofector™ 4D kit for cell lines 
(Lonza, Basel, Switzerland) following manufacturer’s instructions using the C-20 program. For flow 
cytometry experiments 300,000 cells were plated on P100 plastic culture dishes while 10,000 cells 
were plated on four-well dishes (Greiner Bio-one, Frickenhausen, Germany) for 
immunocytochemistry. Three to four hours later (i.e. once the cell adhered) the medium was changed 
to remove dead cells and debris.  
For short term immunocytochemical experiments onto adherent cultures, we used lipofection as a 
transfection method. The day before, 10,000 cells per well were plated in 24-well plates on 20µg/ml 
Poly-L-lysin-coated coverslips (Sigma-Aldrich, St. Louis, MO, United States). The next day, cells were 
transfected with 50µl of Optimem, 0.8µg of DNA and 2µl of Lipofectamine (Invitrogen) per well. Four 
hours later, medium was replaced. 
Flow cytometry 
 Cells were passaged, fixed with ethanol, incubated with RNAse A (50µg/ml, Sigma-Aldrich) and 
filtered through a 70µm cell strainer (BD Biosciences, San Jose, CA, USA) to remove cell aggregates. 
Samples were then stained with propidium iodide (125µg/ml, Sigma-Aldrich) or Hoechst (1.25µl/ml, 
Sigma-Aldrich) depending on the reporter protein of the construct used, and analyzed on a Beckman 
Coulter FC500 (Beckman Coulter, Indianapolis, IN, USA). Doublets were eliminated by forward 
scatter (FSC), side scatter (SSC) area, width and height function dot plots. For cell cycle analyses, data 
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were plotted on gated linear histograms using the WinMDI 2.9 software (free software, 
http://facs.scripps.edu/software.html).  
Immunocytochemistry 
Cells were first blocked in TBS/10% horse serum/0.4% Triton-X-100 (TBS++) and then incubated with 
primary antibodies, washed and incubated with fluorescent conjugated secondary antibodies. Finally 
cells were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI; Invitrogen) and mounted with 
Mowiol. The following primary antibodies and dilutions were used: rabbit α-hOlig2 (1:200, LifeSpan 
Biosciences, Seattle, WA, USA), mouse α-APC (1:500, Calbiochem, Merck KGaA, Darmstadt, 
Germany), chicken α-GFP (1: 1000, Abcam, Cambridge, ENG, United Kingdom), rabbit α-RFP (1: 
500, MBL International Corporation, Woburn, MA, USA ), Rabbit α-Casp3A (1: 500, R&D Systems, 
Minneapolis, MN, USA), mouse α-Ki67 (1: 400, BD Bioscences). Species-matched, cross-absorbed 
AlexaFluor-488/555/647 secondary antibodies were used at 1:1000 (Invitrogen). 
Semi-quantitative Real Time PCR (qPCR) 
All RNA extractions were performed using the Qiagen RNAeasy kit, including a DNAse treatment 
(Qiagen, Valencia, CA, USA). Similar amounts of RNA were converted to cDNA using oligo (dTs) 
and the M-MLV reverse transcriptase (Promega, Madison, WI, USA). 
For each reaction 10ng of cDNA were amplified with specifically designed primers (see Table 1 in 
Supplementary Data) and SybrGreen mix (Roche, Basel, Switzerland) using the Roche LightCycler 
480 technology. Relative gene expression was determined using the ΔΔ-CT method versus the 
housekeeping genes HPRT1 and PPIA. 
For the qPCR array data, RNA extraction was performed as described above and reverse transcription 
as specified by the manufacturer with the RT2 first strand kit (SABiosciences, Roche). The Human 
Cancer Pathway Finder PCR Array (PAHS-033 3.0) was used and the data analyzed with the provided 
Microsoft Excel template using B2M and RPL13A as housekeeping genes. The heat map plot was 
generated using the online analysis tool from SABiosciences and presented as “log2 fold change of 
expression”. 
Lentiviral vectors production and titration 
The production of both lentiviruses was performed as previously described (Barde et al. 2010). The 
inducible pSIN_RFP_hPGK_rtTA2SM21 and pSIN_dnE47RFP_hPGK_rtTA2SM21 lentiviral 
constructs were generated by inserting amplified PCR fragments of RFP and dnE47RFP into MluI 
restriction sites of the pSIN-TRE-mSEAP-hPGK-rtTA2SM21 vector (Barde et al. 2006). Correct 
insertion was verified by sequencing of the fragments of interest. These lentiviral vectors allow tight, 
dose-dependent, inducible control of transgene expression upon doxycyclin (Sigma) exposure.   
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For lentiviral production, 293T cells were transfected with three plamids encoding for the VSV G 
envelope protein, HIV-1 Gag, Pol, Tat and Rev proteins as well as the recombinant vector. All three 
constructs were transfected with Calcium Phosphate and the supernatant collected three times before 
ultracentrifugation (120min, 50’000 x g, 16oC, Beckman Coulter). The titers ranged from 5x108 to 
5x109 IU/ml and were determined by both flow cytometry and qPCR on HCT116 cells. Flow 
cytometry measured the numbers of fluorescent transfected cells and qPCR, the number of copies of 
the lentivirus integrated in the genome of infected cells. 
Sphere Formation Assay 
Glioma-initiating cell lines were infected with 100 IU of lentiviral constructs per cell and seeded at a 
clonal density of 10 cells/µl in 24-well-plates, four wells per condition. The medium containing 
doxycycline (2µl/ml) was replenished every 2nd or 3rd day and the number of spheres and the diameter 
were determined 7 days later. Both bright-field and fluorescence pictures of each well were taken on an 
inverted microscope (Carl Zeiss, Oberkochen, Germany) and overlaid for quantifications on the ImageJ 
software (Rasband WS, ImageJ, Bethesda, MD, USA). Only transfected spheres were considered for 
quantification. The spheres were passaged four times and replated at clonal densities each time. Results 
are the mean of four independent experiments. For qPCR measurements, infected glioma-initiating 
cells were seeded in T75 culture flasks. After 7 days spheres were collected at 300 x g and dissociated. 
Single cells were replated in doxycycline containing growth medium and the RNA extracted 48 hours 
following induction. For RFP/GFP competition experiments, cells were transduced with a constitutive 
GFP lentivirus (pRRLSIN.cPPT.PGK-GFP.WPRE) and mixed 1:1 with cells transduced with either the 
RFP or the dnE47RFP lentivirus. The formation of GFP and RFP positive spheres was monitored over 
three passages. 
Animal studies and tissue processing 
All animal procedures were approved by the Ethics Committee of the Veterinary Department of the 
Canton of Zurich and performed in accordance with Swiss law. T269 cells, previously transduced with 
either the RFP or dnE47RFP lentivirus were transduced with a constitutive GFP lentivirus 
(pRRLSIN.cPPT.PGK-GFP.WPRE) and FACS-sorted to reach a 100% GFP positive population. 
100,000 cells in 3µl were stereotaxically grafted in the right striatum of 7-9 week old female athymic 
mice (CD1nu/nu mice, Charles River, Wilmington, MA, USA). 4.5 weeks post-transplantation, mice 
were divided into 4 groups (n=10): those who received T269 transfected with GFP/RFP (group 1) or 
with GFP/dnE47::RFP (group 2) were treated with doxycycline (2mg/ml, 1% sucrose) in the drinking 
water to induce expression of the construct.  Groups 3 and 4 (transfected with GFP/RFP or 
GFP/dnE47::RFP) received 1% sucrose solution as their respective control. Two weeks following 
doxycycline induction, 3 animals per group were sacrificed for histological analyses and the remaining 
animals (n=7) left to survive until onset of clinical symptoms. Animals were perfused with 4% PFA 
and brains, postfixed for 24 hours in the same fixative and cryoprotected in 30% Sucrose. 50um thick 
brain sections were cut on a sliding microtome and serially collected. To study transduction and 
induction efficiency, free floating sections were washed and, blocked in PB with 1% Triton X-100 
(Sigma-Aldrich, Switzerland) and 10% horse serum (Gibco) for 1h at RT. and incubated with the 
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following primary antibodies: mouse anti-human nuclear antigen (1:500; Millipore, Billerica, MA, 
USA) or rabbit anti-RFP (1:500; MBL International Corporation). Sections were then revealed with the 
corresponding fluorescent conjugated secondary antibodies (1:1000; Life Technologies), 
counterstained with DAPI, mounted and coverslipped with Mowiol. 
Image acquisition and analysis 
Images were acquired using a Leica DM5500 B upright microscope (Leica Microsystems, Mannheim, 
Germany) or a Zeiss Axiovert 10 inverted microscope (Carl Zeiss), for in vivo and in vitro analysis, 
respectively. For all long-term glioma cell lines in vitro immuno-experiments, 4 wells per condition 
were analyzed in 3 independent experiments (n>3). A total of 5 random fields per well were acquired 
and the average over wells was calculated. For all patient-derived glioma-initiating cell in vitro 
experiments, 4 wells per condition were analyzed in 4 independent experiments (n=4). For histological 
analyses, 200 cells per region in three animals (n=3) were randomly selected and analyzed using the 
Leica Software (Leica Microsystems) at 10x (hNA analyses) and 20x (induction efficiency)-fold 
magnification. 
For single cell densitometry, in each experiment (n=3) and condition a total of 20 randomly chosen 
cells per well were imaged using a Leica TCS SPE II confocal microscope (Leica Microsystems). 
Confocal stacks consisting of 10 images (step size 2µm) were acquired using a 40X objective (N.A. 
1.15) and were analyzed using the Leica Software (Leica Microsystems). The compared conditions 
were exposed with the exact same settings and 3 regions of interest were drawn in each cell (nucleus 
and cytoplasm) in order to measure the mean grey value.  
Statistical analyses 
All statistical analyses were performed with Prism 5 (GraphPad Software, La Jolla, CA, USA). 
Analyses are presented as mean + SEM, and samples were compared for significance using unpaired t-
test or ANOVA followed by Tukey’s post-hoc tes, as appropriate. 
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Results	  
 
Human glioma cell lines show heterogeneous patterns and levels of 
expression of class II and V (b)HLH proteins  
We selected two human glioma cell lines (i.e. LN-308 and LNT-229) based on their 
level and pattern of expression of transcripts coding for Class I, II and V bHLH 
proteins. Both cell lines expressed high levels of inhibitors of differentiation 
transcripts (ID1-4), when compared to whole-brain RNA extracts, although with 
marked differences. While both cell lines expressed higher levels of ID1, ID3 was 
shown to be specifically up-regulated in LN-308 cells and ID4 in LNT-229 cells (Fig. 
1A). Class I E47 was enriched only marginally in both cell lines (Suppl. Fig. 2A). 
Measurement of transcript levels for selected Class II bHLH proteins revealed a clear 
difference between the LN-308 cells that express low levels of Olig2, hAscl1 and 
Ngn2 and LNT-229 cells in which these genes were highly transcribed (Fig. 1B, e.g. 
> 1000 fold change for Olig2 compared to whole-brain or LN308 cells RNA). 
Immunodetection and optical density measurements of Olig2 confirmed its 
overexpression in LNT229 cells at the protein level, while the early pan-glial marker 
adenomatous polyposis coli (APC) was expressed at similar levels in both glioma cell 
lines (Fig. 1C-D). 
Altogether, these results reveal that human glioma cell lines express heterogeneous 
levels of (b)HLH transcription factors, which allows comparing the consequences of 
E protein overexpression in the relative presence or absence of Class II bHLH 
dimerization partners.   
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Figure 1 Human glioblastoma cell lines show heterogeneous expression levels of HLH and bHLH 
proteins. A, mRNA expression levels of all four ID proteins compared to whole-brain extract revealed 
enrichment of distinct ID proteins in the LN308 and LNT229 cell lines. B, mRNA expression levels of 
the bHLH transcription factors Olig2, Ascl1 and Ngn2, revealed overexpression of proneural proteins 
in the LNT229 cell line only. C, normalized single cell densitometry for the glial marker APC and 
Olig2, confirmed Olig2 protein enrichment in LNT229 cells.  D, confocal microscopy of hOlig2 
protein expression in LN308 and LNT229 cells. * p < 0.05; *** p < 0.001. Scale bar = 100µm.  
  
	   37	  
E47 overexpression differentially induces cell death in LN-308 and LNT-
229 glioma cells 
We next tested the consequences of E protein overexpression on glioma cell 
proliferation and death. As E proteins have been previously shown to be 
interchangeable, we arbitrarily selected E47 to perform these experiments. We 
overexpressed E47 fused with RFP (E47::RFP) in LN-308 and LNT-229 and analyzed 
the effects onto cell proliferation and cell death  48 hours post-nucleofection by flow 
cytometry and immunostaining. The effects of E47::RFP overexpression on 
proliferation were minimal in both cell lines, with neither changes in the G2/G1 (Fig. 
2A) nor in the percentage of electroporated cells expressing the proliferation marker 
Ki67 (Fig. 2B-C). Surprisingly however, E protein overexpression resulted in a 4-fold 
induction of cell death in LN-308 cells (Fig. 2D) as revealed by the percentage of 
cells detected in the subG1 region (i.e. 5.7 ± 0.1 in controls vs. 20.3 ± 3.8 in E47 
overexpressing cells). Similarly, while only 7.7 ± 2.1% of the LN308 cells transfected 
with a control plasmid expressed the apoptosis marker Caspase3A, this percentage 
was raised to 20.5 ± 1.9% following E47 overexpression (Fig. 2E-F). Interestingly, 
survival of LNT-229 cells was not affected by E47 overexpression (Fig. 2D-F). 
Taken together, E protein overexpression differentially induced cell death in LN-308 
but not in LNT-229 cells, possibly due to their contrasted expression levels of Class II 
bHLH proteins.    
Overexpression of the Class II bHLH proteins Olig2 blocks E47-induced 
cell death in LN-308 glioma cells 
We reasoned that the presence of Class II bHLH proteins (i.e. Olig2) might have 
counteracted E47-mediated apoptosis in LNT229 glioma cells. To test this hypothesis, 
we overexpressed Olig2 alone or together with E47 in LN-308 cells and monitored 
proliferation and cell death after 48 hours. Overexpression of Olig2 proteins increased 
significantly the proliferation of LN308 cells as revealed by flow cytometry (i.e. 
G2/G1 ratio, Suppl. Fig. 3A) and Ki67 immunodetection (Suppl. Fig. 3B). 
Interestingly these changes were not potentiated by co-nucleofection of class II bHLH 
proteins with E47, suggesting they may depend on homodimer formation. In contrast 
to cell proliferation, Olig2 overexpression did not significantly influence cell death in 
LN308 cells, but fully blocked E47-induced apoptosis in LN-308 (Fig. 2G-H). 
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Altogether, these results indicate that Class II bHLH proteins are critically involved in 
glioma cell proliferation and survival, and suggest that their activity must be 
counteracted together with ID proteins in order to achieve anti-glioma effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (next page) E47-induced cell death in glioma cells depends on low Olig2 expression 
levels. A, proliferation was unaffected in either cell line at 48h after nucleofection as seen by the 
G2/G1 ratio. B, the number of RFP/Ki67 positive cells showed similar trends. C, Arrowheads indicate 
transduced LN308 cells positive for Ki67. Higher magnifications show a representative RFP/Ki67+ 
cell. D, the subG1 population percentage was significantly higher in the low-bHLH cell line LN308. E, 
Immunodetection of the apoptotic marker activated-Caspase3 confirmed the flow cytometry data. F, 
Arrowheads show transfected LN308 cells positive for Casp3A. Higher magnifications show a 
representative RFP/Casp3a+ cell. G-H, co-overexpression of E47 and Olig2 blocked E47-induced cell 
death E47 in the LN308 line, as revealed by flow cytometry (G) and Cassp3A immunodetection (H). 
All significances were compared to control; * p<0.05; ** p<0.01; *** p<0.001. Scale bars = 20µm  
(higher magnification scale bar = 10µm ) 
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E47 lacking its nuclear localization signal sequesters Olig2 in the 
cytoplasm and induces cell death in both low and high-bHLH expressing 
gliomas 
The E47 protein forms homodimers or heterodimers with Class II bHLH proteins and 
translocate to the cell nucleus where it is transcriptionally active. As a consequence, 
single-cell densitometry analysis revealed an exclusive nuclear location of the 
E47::RFP fusion protein (Fig. 3A-C). In order to sequester both E47 and its binding 
partners in the cytoplasm, and therefore block their transcriptional activity, we used a 
dominant-negative mutant form of E47 (dnE47) lacking its nuclear localization signal 
(NLS). Single densitometry analysis for RFP confirmed the cytoplasmic localization 
of the dnE47::RFP fusion protein (Fig. 3D-F), as well as the rapid and efficient 
cytoplasmic sequestration of its dimerization partner Olig2 (Fig. 3G). Thus, E47 
proteins can be successfully engineered to prevent their translocation as homo or 
heterodimers to the cellular nucleus and to modulate transcription (see below). 
 
We next tested the consequences of dnE47::RFP overexpression in LNT229 and 
LN308 cells, 48 hours post- transfection. Similarly to E47::RFP, dnE47::RFP 
overexpression had only marginal effects onto glioma cell proliferation (Fig. 3H-J). 
In contrast, the effect of dnE47 overexpression onto glioma cell death was 
pronounced, and observed in both glioma cell lines (Fig. 3K-M). Flow cytometry 
analyses revealed a significant increase in the percentage of cells in subG1 in LN308 
and LNT229 cells, with LNT229 cells showing a stronger response (Fig. 3K). These 
observations were confirmed by analyzing the number of RFP+/Casp3a+ cells (Fig. 
3L-M). The LN-308 glioma cell line exhibited a similar response to dnE47::RFP 
overexpression compared with wtE47::RFP (compare Fig. 2D & 3K) whereas LNT-
229 cells remarkably revealed higher levels of apoptosis. These findings emphasize 
the need to neutralize Class II (b)HLH proteins transcriptional activity to achieve anti-
glioma effects. 
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Figure 3 (next page) Overexpression of E47 lacking its nuclear localization signaling sequesters 
Olig2 in the cytoplasm and induces cell death in both glioma cell lines. A-C, the E47 wild-type protein 
fused to a RFP reporter showed an exclusively nuclear location following electroporation, as quantified 
by single-cell densitometry in LN308 (B) and LNT229 (C) cells. D-F, the mutant form of E47 lacking 
its NLS was retained in the cytoplasm in both cell lines. G, hOlig2 is located in the nucleus or in the 
cytoplasm in LNT229 cells, following overexpression of E47 or dnE47, respectively. H, Flow 
cytometry measurements of the G2/G1 ratios, revealed a reduced proliferation in LNT229 cells 
following dnE47 overexpression. I, No changes in the percentage of RFP/Ki67+ cells was detected. J, 
Arrowheads show transduced LNT229 cells positive for Ki67. Inserts show higher magnifications of a 
representative RFP/Ki67+ cell. K-L, overexpression of dnE47 induced cell death in both glioma lines as 
shown by flow cytometry subG1 measurements  (K) and immunodetection of Casp3A (L). M, 
Arrowheads show transduced LNT229 cells positive for Casp3A. Inserts show higher magnifications 
of a representative RFP/Casp3A+ cell. * p<0.05; ** p<0.01; *** p<0.001; Scale bars = 20µm (higher 
magnification scale bar = 10µm) 
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DnE47 overexpression induces dramatic changes at the gene expression 
level 
Gene expression modifications following dnE47::RFP overexpression in LNT-229 
gliomas was assayed by qPCR at 48 hours following transfection using an array of 
genes representative of six biological pathways involved in transformation and 
tumorigenesis (see Material and Methods and Suppl. Table S4). Overexpression of 
E47::RFP induced minimal transcriptional changes in LNT-229 (Fig. 4A), in 
agreement with the minor phenotypic changes described above. In contrast, 
overexpression of dnE47::RFP induced marked gene expression modifications 
throughout (Fig. 4B). In particular, genes involved in cell cycle and apoptosis were 
only significantly induced following dnE47::RFP overexpression (Fig. 4C). These 
include, CDC25A and BCL2L1 that were significantly down-regulated following 
dnE47::RFP overexpression, consistent with reduced proliferation and increased cell 
death observed in LNT-229 glioma cells, respectively. These data were confirmed by 
qPCR using self-designed primers (Fig. 4D-E).  
Taken together, these results highlight superiority of dnE47::RFP over E47::RFP in 
disrupting gene expression in glioma cells, in particular the expression of pro-
proliferative and anti-apoptotic genes. 
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Figure 4 Overexpression of dnE47 in LNT229 glioma cells induces down-regulation of pro-
proliferative and anti-apoptotic genes. A, changes in gene expression representative of six biological 
pathways involved in transformation and tumorigenesis were minor after E47 overexpression in 
LNT229 cells. B, dnE47 overexpression induced more pronounced changes in gene expression levels. 
C, E47 overexpression did not influence the expression of genes involved in proliferation and apoptosis 
whereas dnE47 significantly altered their expression levels. D-E, 48h after transfection, qPCR 
confirmed that mRNA levels of CDC25a (D, B01 in A and B) and BCL2L1 (E, A09 in A and B) were 
significantly reduced. Heatmap: log2 fold change. * p<0.05; ** p<0.01 
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DnE47 efficiently reduces the sphere-forming capacity of glioma-
initiating cells 
We next expanded our studies with 2 patient-derived glioma-initiating cells (T269 and 
S24). qRT-PCR analysis revealed an enrichment for the common stem-cell marker 
Nestin in both T269 and S24 cells, when compared with whole brain RNA (Fig. 5A). 
Similarly to glioma cell lines, high levels of Class II bHLH transcripts expression, in 
particular of Olig2 (Fig. 5A), as well as specific ID proteins transcripts were detected 
(Fig. 5B), while E protein transcripts were only marginally enriched (Suppl. Fig. 2B).  
A clonogenic sphere assay was next performed to examine dnE47 overexpression on 
self-renewal and survival in glioma-initiating cells. Cells were transduced with a 
doxycycline-inducible lentivirus coding for dnE47::RFP or RFP as a control. T269 
and S24 cells were plated at clonal densities (10 cells/µl) and the number of spheres 
and their diameter were analyzed every 7 days, prior and over four subsequent 
passages following transgene induction (i.e. 2ug/ml of doxycyclin). Induction of 
dnE47::RFP expression in T269 cells resulted in a decreased number of large (>90 
µm) as well as medium-sized (70-90µm) spheres, that could already be observed at 
the 1st passage (i.e. 1 week post-induction. Fig. 5C). At the 4th passage, dnE47::RFP 
dramatically decreased the number of spheres in all size categories, to values <25% to 
controls, (Fig. 5D & E). Similarly to glioma cell lines, quantification of gene 
expression 48 hours post-induction revealed that Cdc25A and Bcl2-L1 were 
significantly down-regulated in dnE47::RFP transduced cells (Fig. 5F), suggesting 
that changes in proliferation and survival could contribute to sphere loss. In addition, 
a 60% reduction of Nestin expression was observed following dnE47::RFP induction 
(Fig. 5F), supporting loss of stemness. To more directly assess the anti-glioma effects 
of dnE47::RFP over-expression, T269 cells transduced with a constitutive control 
GFP lentivirus or an inducible dnE47::RFP lentivirus were mixed (1:1) and the 
number of GFP+ and RFP+ neurospheres quantified prior or following doxycycline-
treatment. Induction in both cell lines showed a rapid and strong decrease of RFP 
expressing spheres (~40%) already at the 1st passage (P1). Strikingly, RFP-expressing 
spheres were almost extinguished at the 2nd and 3rd passages, illustrating their marked 
disadvantage compared to control GFP-expressing spheres (Fig. 5G-H). Similar 
results were obtained with S24 cells, demonstrating the robustness and consistency of 
dnE47 overexpression as an anti-glioma strategy (Suppl. Fig. 5). 
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Figure 5 (next page). Patient-derived glioma-intiating cells express high levels of (b)HLH 
transcripts and show reduced sphere formation capacities upon dnE47 overexpression. A, both S24 and 
T269 glioma-intiating cells showed enrichment for the stem cell Nestin transcript as well as for Olig2 
and hAscl1 transcripts. B, their expression profile of ID proteins transcripts is more heterogeneous. C, 
following dnE47 overexpression in T269 glioma-initiating cells, medium and large sphere numbers 
were reduced at the first passage compared to RFP overexpression. D, sphere numbers of all sizes were 
reduced within four passages. E, the total number of spheres dropped significantly after dnE47 
overexpression over passages. F, the reduction in sphere formation capacities correlates with a lower 
expression of genes coding for the pro-proliferative marker CDC25A, the anti-apoptotic protein 
BCL2L1 and the stem-cell marker Nestin. G, when mixed with GFP-expressing spheres at a ratio of 
1:1, the number of dnE47::RFP-overexpressing spheres rapidly declined. H, representative picture of 
GFP and dnE47::RFP mixed sphere cultures. * p<0.05; ** p<0.01; *** p<0.001. Scale bar = 100µm 
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Overexpression of dnE47 delays the onset of clinical symptoms following 
T269 glioma xenografts  
 Finally, we investigated the effects of dnE47 overexpression in vivo by using a 
doxycylin-inducible gene expression approach in established T269 glioma xenografts. 
First, T269 cells were co-transduced with a constitutive GFP and an inducible RFP or 
dnE47-RFP lentiviral construct. Then, these ex vivo transduced T269 cells were 
grafted into the right striatum of athymic mice. Histological analysis on day 30 (i.e. 
before doxycycline administration) showed that all transplanted T269 glioma cells, 
identified by their expression of the human nuclear antigen, were GFP-positive in the 
corpus callosum, the subventricular zone and the fimbriae hippocampi (Fig. 6A). 
Forty-five days post-transplantation, doxycycline was administered in the drinking 
water to induce dnE47-RFP or RFP expression in the established T269 experimental 
glioma. Because both constructs contained an RFP reporter protein, we monitored the 
subcellular localization of the induced target protein by RFP fluorescence. The 
efficiency of doxycyline-mediated induction in vivo was high for both constructs with 
grafted GFP cells being 97.6 ± 0.2% RFP positive in the control group; whereas 90.7 
± 0.4% of the cells expressed the dnE47 construct (Fig.6B). As before, the RFP signal 
was localized only in the cytoplasm upon induction of dnE47 expression but the RFP 
signal in control-transfected glioma cells was distributed ubiquitously in cellular 
compartments (Fig. 6C left and right, respectively). In parallel, we monitored all 
glioma-bearing mice daily and sacrificed them at onset of clinical symptoms. Upon 
doxycycline administration, the median survival for the RFP control group was of 75 
days whereas >60% of dnE47-glioma-bearing mice remained symptom-free beyond 
90 days (Fig.6D).  
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Figure 6. The induction of dnE47 expression in experimental gliomas delays the onset of clinical 
symptoms. A, all human nuclear antigen (hNA) transplanted glioma cells were positive for GFP. B, 
detection of RFP expression revealed that doxycycline-mediated induction of transgene expression in 
vivo was efficient with both the RFP and dnE47::RFP lentiviral vectors. C, the RFP reporter signal was 
localized in the whole cell body when the control RFP lentivirus was induced (left) whereas the RFP 
signal was only localized in the cytoplasm upon doxycyline-mediated induction of dnE47-RFP (right). 
D, dnE47 overexpression prolonged the survival of tumor bearing mice. SVZ: subventricular zone ; 
CC: corpus callosum ; HFi: Fimbria Hippocampi. * p<0.05. Scale bar = 20µm 
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Discussion	  	  
	  
The pro-tumorigenic features of Class II and V proteins in glioma cells call for the 
establishment of a feasible therapeutic anti-cancer strategy by disrupting (b)HLH 
transcriptional networks. Here we used E proteins in order to target (b)HLH 
transcriptional networks in glioma cells because of their ability to bind all ID proteins 
with identical affinity (Massari & Murre 2000; Teachenor et al. 2012) as well as the 
proneural proteins Olig2 and Ascl1 (Samanta & Kessler 2004; Geoffroy et al. 2009).  
By investigating the consequences of E proteins overexpression in glioma cell lines 
expressing low or high levels of Class II (b)HLH proteins, our results show that the 
nuclear translocation/transactivation of proneural proteins by E proteins should be 
prevented in order to achieve anti-glioma responses. Thus, although E47 
overexpression was sufficient to induce cell death in the low Olig2-expressing cell 
line LN-308, it failed to show the same effect in the LNT-229 cell line, which 
expresses high levels of Olig2. Furthermore, these pro-apoptotic effects were blocked 
in LN-308 cells by co-transfection of E47 with Olig2, confirming its rescuing role on 
the observed phenotype. We used a dominant-negative approach in which E proteins 
were engineered to prevent their nuclear translocation without affecting their 
dimerization pattern (Mehmood et al. 2009; Murre, McCaw, Vaessin, et al. 1989), 
resulting in cytoplasmic sequestration of Class II and V (b)HLH proteins (our results; 
(Murre, McCaw, Vaessin, et al. 1989; Deed et al. 1996). Accordingly, the anti-glioma 
effects of dnE47 overexpression were consistently superior to wtE47 in all glioma cell 
lines tested despite important differences in proneural protein expression pattern. 
Our results revealed significant changes in expression levels of several cell cycle 
protein transcripts (i.e. CCNE1, CDC25A and CDK2). However, direct measurements 
of cycling cells by flow cytometry and immunostaining was not possible as their 
detection was obscured from the strongly induced apoptosis (see below). These anti-
proliferative properties are likely to be mediated by sequestration of ID proteins 
whose overexpression has been associated with increased proliferation in several cell 
types (Christy & Nathans 1989; Murphy & Norton 1990; Ruzinova & Benezra 2003), 
by directly interacting and inhibiting proteins of the small retinoblastoma family (Rb, 
p107, p130; (Sherr 1996; Iavarone et al. 1994; Lasorella et al. 1996). In addition, ID 
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proteins are known to inhibit Ets-mediated transcription of P16lnk4a, a tumor 
suppressor gene operating in a common pathway as Rb (Ohtani et al. 2001; Ouyang et 
al. 2002). In parallel, our results demonstrate an enhanced proliferation in glioma cell 
lines following Olig2 or Ascl1 overexpression. These results support a role for 
proneural proteins in promoting glioma cell proliferation, in agreement with previous 
studies showing regulation of neural progenitors and glioma cells by proneural gene 
overexpression and/or phosphorylation (Ligon et al. 2004; Ligon et al. 2007; Sun et 
al. 2011; Castro et al. 2011). 
A pronounced apoptosis response was observed following E proteins overexpression 
in glioma cell lines.  Such a pro-apoptotic effect of E proteins has been previously 
described in other cell types. Overexpression of E2A lead to apoptosis in 293T cells 
whereas ectopic expression of E47 or E12 proteins promoted cell death in E2A-
deficient lymphomas (Engel & Murre 1999a; Pagliuca et al. 2000). Restoration of 
E2A activity in Jurkat leukemic T cells resulted in an inhibition of cell growth and 
induction of cell death associated with an increase in apoptotic cells (Park et al. 
1999), suggesting that bHLH proteins and in particular ID proteins might be 
promoting cell growth by inhibiting apoptosis in specific settings (Norton & Atherton 
1998).  Our results revealed superior and consistent effects following dnE47 
overexpression compared to wtE47, highlighting the need to concomitantly neutralize 
ID and proneural proteins activity to achieve pro-apoptotic responses. Interestingly, 
although our data phenocopied these previous observations, they revealed that these 
effects were only visible in cells expressing low levels of proneural proteins such as 
Olig2. These observations highlight a role for Olig2 in tumor cell survival, possibly 
through its interaction with p53 (Mehta et al. 2011). In addition, our gene expression 
analyses revealed Bcl2 and Bcl2l1 are downstream target genes through which E 
proteins mediate apoptosis. It is known that the expression of anti-apoptotic Bcl2 
proteins increases over time during tumor evolution and support an invasive 
phenotype in glioma cells (Weiler et al. 2006). Furthermore, overexpression of Bcl2 
familly proteins in glioma prevents cell death both in vitro and in vivo (Roth et al. 
2000; Weiler et al. 2006). 
Patient-derived glioma-initiating cells can be grown in the presence of LIF, FGF2 and 
EGF, and mirror more closely the phenotype and genotype of primary tumors than 
serum-cultured cell lines (Lee et al. 2006). As a consequence, contrasting results have 
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for example been obtained for the role of proneural proteins in promoting human 
glioma cell lines and patient-derived glioma-initiating cells differentiation (Tabu et al. 
2006; Ligon et al. 2007). Importantly, our results in T269 and S26 lines confirmed the 
anti-glioma effects observed following dnE47 overexpression. The sphere formation 
capacity of glioma-initiating cells was rapidly and sustainably reduced following 
induction of dnE47 expression when compared with control-transduced cells. 
Modifications to proliferation and apoptosis are likely to jointly participate to these 
effects. Indeed, our qPCR data confirmed in glioma-initiating cells the down-
regulation of CDC25A and BCL2-L1 upon dnE47 overexpression, as observed in LN-
308 and LNT-229 cells. In addition, Nestin transcripts were down-regulated 
suggesting changes in patient-derived tumor-initiating cell stemness (Singh et al. 
2003; Singh et al. 2004). Finally, we confirmed these in vitro observations in a 
xenograft model. Intrastriatal transplantation of T269 glioma-initiating cells led to the 
formation of diffusely infiltrating glioma, similar to the GB phenotype in patients. 
Following doxycycling application, the induction of dnE47 could be readily obtained 
in vivo (Siolas & Hannon 2013). Induction of dnE47 expression was however 
markedly prominent around the ventricular zone, possibly reflecting better drug 
diffusion in this region. Here, induction of dnE47 confirmed our in vitro results by 
showing cytoplasmic distribution and by significantly prolonging the survival of 
tumor bearing animals.  
Altogether, our results highlight that neutralization of bHLH transcriptional networks 
by cytoplasmic sequestration is feasible. Thus, although transcription factors have 
often been considered to be “undruggable” owing to the nuclear location, dynamic 
expression and functional redundancy, simultaneous cytoplasmic sequestration of 
multiple transcription factors by mutating their dimerization partners might represent 
a novel path for designing anti-glioma intervention strategies.   
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Supplementary	  Data	  
Supplementary Table S1. List of primers used for quantitative real time PCR experiments.  
 
Supplementary Table S1 
Gene Sequence 
Amplicon 
lenght 
To and 
Elongation 
time 
HPRT1 fw CTGGCGTCGTGATTAGTGAT 
134 bp 62°, 6sec 
HPRT1 rev AGCAAGACGTTCAGTCCTGT 
PPIA fw TTCATCTGCACTGCCAAGAC 
39 bp 62°, 7sec 
PPIA rev CTTGCCATCCAACCACTCA 
Id1 fw  CACCCTCAACGGCGAGAT 
146 bp 62°, 6sec 
Id1 rev CCACAGAGCACGTAATTCCTC 
Id2 fw AGCCTGCATCACCAGAGAC 
99 bp 62°, 4sec 
Id2 rev TTCAGAAGCCTGCAAGGAC 
Id3 fw  AAATCCTACAGCGCGTCATCG 
129 bp 6 sec 
Id3 rev AGATGACAAGTTCCGGAGTGAG 
Id4  QuantiTect Primer Assay QT00234920, Qiagen 149 bp 62°, 6sec 
CDC25a fw CTTCACACAGAGGCAGAACT 
139 bp 62°, 6sec 
CDC25a rev GCCATCATCCTCATCAGAC 
Bcl-xl fw CCACTTACCTGAATGACCACC 
96 bp 62°, 4sec 
Bcl-xl rev TCTCGGCTGCTGCATTGTT 
Olig2 fw TAGATCGACGCGACACCAG 
133 bp 62°, 6sec 
Olig2 rev GGAAGATAGTCGTCGCAGC 
hAscl1 fw CGACTTCACCAACTGGTTCTG 
118 bp 62°, 5sec 
hAscl1 rev CCAACGCCACTGACAAGAA 
Nestin fw AGACTTCCCTCAGCTTTCAGGAC 
93 bp 64°, 4sec 
Nestin rev TCAGGACTGGGAGCAAAGATCC 
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Supplementary Figure S2. E47 is ubiquitously expressed in cancer cells although at various 
levels. A, qPCR revealed similar or enriched E47 transcript levels in LN308 and LNT229 cells, 
respectively, when compared with whole brain extracts. B, S24 cells showed lower levels and T269 
higher E47 transcripts levels when compared with whole brain extracts. *** p<0.001  
 
Supplementary Figure S3. Co-overexpression of E47 and Olig2 enhanced proliferation in the 
LN308 line. A, an increased proliferation was detected in the LN308 cell line following transfection of 
Olig2 or E47 + Olig2, as revealed by flow cytometry measurements of the G2/G1 ratio. B, Similar 
results were obtained by immunodetection of Ki67 in the transfected (i.e. GFP-positive) cells. All 
significances were compared to control; **p<0.01; ***p<0.001  
 
Supplementary Table S4. List of up- or down-regulated genes from the Human Cancer Pathway 
Finder PCR Array following wtE47 and dnE47 overexpression.  
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Supplementary Table S4 
   wtE47 dnE47 
Gene name Ref Seq Gene description up/down 
regulation 
p 
value 
up/down 
regulation 
p value 
       
Cell Cycle Control and DNA Damage Repair     
ATM  NM_000051  Ataxia telangiectasia 
mutated  
-1.01 0.87 1.13 0.51 
BRCA1  NM_007294  Breast cancer 1, early 
onset  
1.01 0.95 -1.09 0.47 
CCNE1  NM_001238  Cyclin E1  -1.17 0.12 -1.34 0.01** 
CDC25A  NM_001789  Cell division cycle 25 
homolog A (S. pombe)  
-1.44 0.16 -2.08 0.01** 
CDK2  NM_001798  Cyclin-dependent 
kinase 2  
-1.10 0.28 -1.24 0.05* 
CDK4  NM_000075  Cyclin-dependent 
kinase 4  
1.01 0.89 1.03 0.89 
CDKN1A  NM_000389  Cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1)  
1.67 0.13 1.32 0.30 
CDKN2A  NM_000077  Cyclin-dependent 
kinase inhibitor 2A 
(melanoma, p16, 
inhibits CDK4)  
1.77 0.32 2.44 0.31 
CHEK2  NM_007194  CHK2 checkpoint 
homolog (S. pombe)  
-1.29 0.22 1.03 0.77 
E2F1  NM_005225  E2F transcription 
factor 1  
-1.14 0.57 -1.84 0.10 
MDM2  NM_002392  Mdm2 p53 binding 
protein homolog 
(mouse)  
-1.16 0.55 -1.05 0.83 
RB1  NM_000321  Retinoblastoma 1  1.07 0.46 1.10 0.39 
S100A4  NM_002961  S100 calcium binding 
protein A4  
-1.08 0.59 1.02 0.92 
TP53  NM_000546  Tumor protein p53  -1.06 0.60 1.22 0.14 
       
Apoptosis and Cell Senescence     
APAF1  NM_001160  Apoptotic peptidase -1.09 0.69 -1.15 0.60 
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activating factor 1  
BAD  NM_004322  BCL2-associated 
agonist of cell death  
1.27 0.57 1.25 0.58 
BAX  NM_004324  BCL2-associated X 
protein  
-1.07 0.82 -1.32 0.19 
BCL2  NM_000633  B-cell CLL/lymphoma 
2  
-1.36 0.18 -1.93 0.01** 
BCL2L1  NM_138578  BCL2-like 1  -1.30 0.52 -2.48 0.05* 
CASP8  NM_001228  Caspase 8, apoptosis-
related cysteine 
peptidase  
1.08 0.56 1.17 0.39 
CFLAR  NM_003879  CASP8 and FADD-
like apoptosis 
regulator  
-3.90 0.85 1.15 0.45 
FAS  NM_000043  Fas (TNF receptor 
superfamily, member 
6)  
1.33 0.19 1.10 0.62 
GZMA  NM_006144  Granzyme A 
(granzyme 1, cytotoxic 
T-lymphocyte-
associated serine 
esterase 3)  
1.27 0.34 1.20 0.31 
HTATIP2  NM_006410  HIV-1 Tat interactive 
protein 2, 30kDa  
1.20 0.41 1.07 0.59 
TERT  NM_198253  Telomerase reverse 
transcriptase  
-1.61 0.21 -2.01 0.40 
       
Signal Transduction Molecules and Transcription 
Factors 
    
AKT1  NM_005163  V-akt murine 
thymoma viral 
oncogene homolog 1  
-1.05 0.86 -1.23 0.62 
ERBB2  NM_004448  V-erb-b2 
erythroblastic 
leukemia viral 
oncogene homolog 2 
-1.74 0.10 -1.45 0.53 
ETS2  NM_005239  V-Ets erythroblastosis 
virus E26 oncogene 
homolog 2 (avian)  
1.17 0.48 -1.03 0.94 
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FOS  NM_005252  V-fos FBJ murine 
osteosarcoma viral 
oncogene homolog  
-1.81 0.24 1.42 0.27 
JUN  NM_002228  Jun oncogene  1.39 0.46 -2.20 0.12 
MAP2K1  NM_002755  Mitogen-activated 
protein kinase kinase 1  
1.07 0.09 -1.13 0.30 
MYC  NM_002467  V-myc 
myelocytomatosis 
viral oncogene 
homolog (avian)  
-1.88 0.05* -1.66 0.15 
NFKB1  NM_003998  Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 1  
-1.13 0.72 1.09 0.49 
NFKBIA  NM_020529  Nuclear factor of kappa 
light polypeptide gene 
enhancer in B-cells 
inhibitor, alpha  
1.45 0.33 1.59 0.25 
PIK3R1  NM_181504  Phosphoinositide-3-
kinase, regulatory 
subunit 1 (alpha)  
-1.20 0.13 1.01 0.88 
RAF1  NM_002880  V-raf-1 murine 
leukemia viral 
oncogene homolog 1  
-1.15 0.07 -1.20 0.01** 
SNCG  NM_003087  Synuclein, gamma 
(breast cancer-specific 
protein 1)  
1.54 0.28 1.60 0.35 
TNFRSF10
B  
NM_003842  Tumor necrosis factor 
receptor superfamily, 
member 10b  
-1.09 0.55 -1.17 0.43 
TNFRSF1A  NM_001065  Tumor necrosis factor 
receptor superfamily, 
member 1A  
-1.19 0.44 1.00 0.91 
TNFRSF25  NM_003790  Tumor necrosis factor 
receptor superfamily, 
member 25  
1.35 0.54 -1.04 0.92 
       
Adhesion       
ITGA1  NM_181501  Integrin, alpha 1  -1.03 0.94 1.55 0.05* 
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ITGA2  NM_002203  Integrin, alpha 2 
(CD49B, alpha 2 
subunit of VLA-2 
receptor)  
1.00 0.69 -1.34 0.26 
ITGA3  NM_002204  Integrin, alpha 3 
(antigen CD49C, alpha 
3 subunit of VLA-3 
receptor)  
-1.12 0.96 -1.80 0.23 
ITGA4  NM_000885  Integrin, alpha 4 
(antigen CD49D, 
alpha 4 subunit of 
VLA-4 receptor)  
1.05 0.63 1.15 0.19 
ITGAV  NM_002210  Integrin, alpha V 
(vitronectin receptor, 
alpha polypeptide, 
antigen CD51)  
1.20 0.21 1.41 0.05* 
ITGB1  NM_002211  Integrin, beta 1 
(fibronectin receptor, 
beta polypeptide, antigen 
CD29 includes MDF2, 
MSK12)  
-1.04 0.89 -1.20 0.39 
ITGB3  NM_000212  Integrin, beta 3 
(platelet glycoprotein 
IIIa, antigen CD61)  
-1.31 0.80 1.26 0.45 
ITGB5  NM_002213  Integrin, beta 5  1.20 0.49 -1.16 0.51 
MCAM  NM_006500  Melanoma cell 
adhesion molecule  
-1.12 0.56 -1.55 0.15 
MTSS1  NM_014751  Metastasis suppressor 
1  
1.27 0.34 1.23 0.29 
PNN  NM_002687  Pinin, desmosome 
associated protein  
-1.21 0.08 -1.15 0.28 
SYK  NM_003177  Spleen tyrosine kinase  1.59 0.31 1.57 0.08 
       
Angiogenesis      
ANGPT1  NM_001146  Angiopoietin 1  -1.91 0.30 -1.44 0.12 
ANGPT2  NM_001147  Angiopoietin 2  -1.19 0.75 -1.12 0.68 
COL18A1  NM_030582  Collagen, type XVIII, 
alpha 1  
1.62 0.05* 1.37 0.07 
FGFR2  NM_000141  Fibroblast growth 1.27 0.34 1.14 0.45 
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factor receptor 2  
IFNA1  NM_024013  Interferon, alpha 1  -1.01 0.70 -1.32 0.11 
IFNB1  NM_002176  Interferon, beta 1, 
fibroblast  
1.23 0.40 1.37 0.33 
IGF1  NM_000618  Insulin-like growth 
factor 1 (somatomedin 
C)  
-1.42 0.57 1.10 0.99 
IL8  NM_000584  Interleukin 8  -1.22 1.00 1.70 0.56 
PDGFA  NM_002607  Platelet-derived 
growth factor alpha 
polypeptide  
1.22 0.29 1.91 0.05* 
PDGFB  NM_002608  Platelet-derived growth 
factor beta polypeptide 
(simian sarcoma viral (v-
sis) oncogene homolog)  
7.63 0.11 2.19 0.13 
TEK  NM_000459  TEK tyrosine kinase, 
endothelial  
2.03 0.10 -1.01 0.86 
TGFB1  NM_000660  Transforming growth 
factor, beta 1  
1.41 0.26 -1.78 0.05* 
TGFBR1  NM_004612  Transforming growth 
factor, beta receptor 1  
1.18 0.27 1.43 0.05 
THBS1  NM_003246  Thrombospondin 1  -1.35 0.35 -3.31 0.001**
* 
TNF  NM_000594  Tumor necrosis factor 
(TNF superfamily, 
member 2)  
2.23 0.33 2.24 0.19 
EPDR1  NM_017549  Ependymin related 
protein 1 (zebrafish)  
-1.05 0.62 -1.17 0.18 
VEGFA  NM_003376  Vascular endothelial 
growth factor A  
1.57 0.05* -1.46 0.38 
       
Invasion and Metastasis     
MET  NM_000245  Met proto-oncogene 
(hepatocyte growth 
factor receptor)  
-1.09 0.60 -2.07 0.05* 
MMP1  NM_002421  Matrix 
metallopeptidase 1 
(interstitial 
collagenase)  
2.40 0.43 -1.47 0.30 
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MMP2  NM_004530  Matrix metallopeptidase 
2 (gelatinase A, 72kDa 
gelatinase, 72kDa type 
IV collagenase)  
1.08 0.54 -1.04 0.85 
MMP9  NM_004994  Matrix 
metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type 
IV collagenase)  
1.51 0.33 1.55 0.38 
MTA1  NM_004689  Metastasis associated 
1  
-1.30 0.21 -1.37 0.05* 
MTA2  NM_004739  Metastasis associated 
1 family, member 2  
-1.01 0.94 -1.37 0.51 
NME1  NM_000269  Non-metastatic cells 1, 
protein (NM23A) 
expressed in  
-1.16 0.20 -1.11 0.08 
NME4  NM_005009  Non-metastatic cells 4, 
protein expressed in  
1.21 0.46 1.49 0.15 
PLAU  NM_002658  Plasminogen activator, 
urokinase  
2.83 0.24 3.21 0.26 
PLAUR  NM_002659  Plasminogen activator, 
urokinase receptor  
-1.27 0.33 -1.77 0.05* 
SERPINB5  NM_002639  Serpin peptidase 
inhibitor, clade B 
(ovalbumin), member 5  
-1.64 0.05* -2.40 0.01** 
SERPINE1  NM_000602  Serpin peptidase 
inhibitor, clade E 
(nexin, plasminogen 
activator inhibitor type 
1), member 1  
-1.12 0.69 -2.49 0.01** 
TIMP1  NM_003254  TIMP 
metallopeptidase 
inhibitor 1  
1.16 0.55 1.07 0.49 
TIMP3  NM_000362  TIMP 
metallopeptidase 
inhibitor 3  
-1.47 0.50 1.09 0.72 
TWIST1  NM_000474  Twist homolog 1 
(Drosophila)  
-1.18 0.35 1.09 0.65 
 
	   62	  
 
Supplementary Figure S5. Patient-derived glioma-intiating cells show reduced sphere formation 
capacities upon dnE47 overexpression. A-B, following dnE47 overexpression in S24 glioma-intiating 
cells, spheres numbers of all size categories were rapidly reduced. C, the total number of spheres 
dropped significantly after dnE47 overexpression over passages. D, representative pictures of control 
RFP spheres (left) and dnE47::RFP expressing spheres (right) at passage 4 following doxycycline 
induction. E, the reduction in sphere formation capacities correlates with a lower expression of the pro-
proliferative gene CDC25A, the anti-apoptotic gene BCL2L1 and the stem-cell gene Nestin. F, when 
mixed with GFP-expressing spheres at a ratio of 1:1, the number of dnE47::RFP-overexpressing S24 
spheres declined rapidly. * p<0.05; ** p<0.01; *** p<0.001; Scale bars = 100µm  
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Abstract	  
	  
In this chapter, I describe the establishment and design of tools and methods to 
investigate the impact of (b)HLH transcriptional network disruption onto human 
tumor-initiating cells. First, we cloned a mutated form of E47RFP and a control RFP 
into a Doxycycline inducible lentiviral vector. Then, high titer lentivirus batches were 
produced and finally, the optimal conditions for transduction and induction of the 
lentivirus in tumor-initiating cells were established. Having the tools at hand, we next 
tested the best culturing conditions for sphere formation analyses for both T269 and 
S24 tumor-initiating cells. As a last step, we tested the influence of dnE47 on tumor 
formation in a murine xenograft model. For this, we chose the T269 tumor-initiating 
cell line, as its invading capacity was higher than that of the S24 cell line mirroring 
more closely the behavior of human glioblastoma tumors. The key results obtained in 
this series of experiments have been presented in chapter II and here, a more detailed 
description of tumor morphology will be presented. Finally, examples of possible 
histological interpretations and an outlook for further analyses will be discussed.  
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Introduction	  
	  
In vivo cell labeling and transgenesis took a new turn in 1996 when Naldini and 
colleagues demonstrated the efficient and stable transduction of neurons in vivo with a 
human immunodeficiency virus (HIV)-derived retrovirus (Naldini et al. 1996). 
Compared with other virus types commonly used in research such as retroviruses, 
adenoviruses or adeno-associated viruses (AAV), lentiviruses present the advantage 
to infect both dividing and non-dividing cells (O’Connor & Crystal 2006). 
Lentiviruses are a subclass of HIV-derived retroviruses, are replication-defective and 
have been adapted for highly efficient gene delivery in vitro and in vivo. Over time, 
engineering of the packaging vectors was improved and HIV safety issues were 
resolved by keeping only three out of nine viral genes: gag, pol and rev in the viral 
backbone (Zufferey et al. 1997). The gene delivery vectors were modified over time 
to bring three major improvements that led to the emergence of second-generation 
constructs. First, the Woodchuck Hepatitis Virus Post-transcriptional Regulatory 
Element (WPRE) was added in order to improve transcription (Zufferey et al. 1999). 
Second, the transgene RNA retains the central polypurine tract of HIV for high titer 
productions (Follenzi et al. 2000; Zennou et al. 2000). Third, removal the U3 3’ LTR 
(long terminal repeat) region containing the viral promoter in its RNA genome 
rendered the vectors unable to replicate themselves, i.e. self-inactivating (SIN) 
(Zufferey et al. 1998). These second-generation vectors provide sufficient 
transduction efficiency and biosafety for in vitro and in vivo research. In the case of 
clinical research and gene delivery therapies, third-generation vectors with an 
engineered chimeric 5’ LTR enabling promoter recruitment in the absence of the Tat 
gene provide a safer lentiviral system (Dull et al. 1998). For our purposes, we used a 
second-generation self-inactivating gene delivery vector: pSIN 
_hPGK_rtTA2SM21(Barde et al. 2006).  
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A new area in cancer research started when a subpopulation of cancer stem cells that 
are able to induce tumors and are responsible for relapse after therapy, were 
discovered within brain tumors (Singh et al. 2003; Singh et al. 2004; Chen et al. 
2010). As they appeared to resist to therapy, targeting these cells became a major goal 
in the development of new therapeutic approaches (Chen et al. 2012; Schonberg et al. 
2013). Since then, research aimed at characterizing the origin of brain cancer stem 
cells, their role in tumor homeostasis and their genetic profile in order to overcome 
their resistance to treatments (Tabatabai & Weller 2011; Schonberg et al. 2013; Stiles 
& Rowitch 2008). Investigating their abilities to form and sustain tumors involved 
challenging cancer stem cells in an in vivo system and implied the use of xenograft 
models: to investigate how human cancer stem cells react to therapies, studies took 
advantage of well-established mammalian transplantation systems, mainly using 
rodents lacking an immune system (Flanagan 1966; Greiner et al. 1995; Christianson 
et al. 1997; Mecklenburg et al. 2001; Siolas & Hannon 2013). 
 
In this chapter, we will describe and discuss how the tools and experimental setup for 
assessing the effects of mutant E proteins overexpression in glioma-initiating cells 
were developed in vitro and in vivo. Finally, possible methodological approaches for 
advanced histological analyses, e.g. for assessing the distribution of grafted tumor-
initiating cells, will be presented and described for future follow-up in vivo studies. 
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1.	  Building	  the	  tools	  
	  
1.1 Vector	  cloning	  
	  
In order to express our genes of interest in a controlled manner, we selected an 
inducible lentivirus approach. For this, we received from Dr. Isabelle Barde 
(Transgenic Core Facility, EPFL) the following second-generation transfer vector: 
pSIN_mSEAP_hPGK_rtTA2SM21. This vector permits a tight and dose-dependent 
control of its expression upon application of a Tetracycline analogue: Doxycycline 
(Barde et al. 2006). First, the mSEAP gene was cut out with the sticky end restriction 
enzyme MluI and Pfx. Next, polymerase-amplified PCR fragments of RFP or 
dnE47RFP were inserted. Correct insertion of the fragments was verified by control 
digestion of the whole vector as well as by sequencing. Cloning procedures for both 
genes generated two inducible vectors: pSIN_RFP_hPGK_rtTA2SM21 and 
pSIN_dnE47RFP_hPGK_rtTA2SM21 (Fig1). 
 
	  
Figure 1 Explanatory scheme of the lentiviral vectors pSIN_RFP_hPGK_rtTA2SM21 and 
pSIN_dnE47RFP_hPGK_rtTA2SM21engineered for this study.  
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1.2 Lentivirus	  production	  
	  
For lentivirus production, human 293T Hek cells were transfected with three plamids: 
one encoding for the VSV G envelope protein, one for the HIV-1 Gag, Pol, Tat and 
Rev proteins as well as the third-generation transfer vector. All three constructs were 
transfected with Calcium Phosphate and the supernatant containing the virus particles 
was collected three times before being concentrated by ultracentrifugation (120min, 
50’000 x g, 16oC, Beckman). The titer was determined by both flow cytometry and 
qRT-PCR on HCT116 cells (human colorectal carcinoma). For this, the cells were 
infected with serially diluted IFU/cell concentrations and harvested after 3 days. The 
percentage of fluorescent transfected cells upon Doxycycline induction were 
measured by flow cytometry and the number of copies of the lentivirus integrated in 
the genome of infected cells by qRT-PCR (Barde 2010). An approximate final 
volume of 150 µl was collected. The following titers were obtained: 5*108 IU/ml for 
the pSIN_RFP vector and 5*109 IU/ml for the pSIN_dnE47 vector. 
1.3 Optimizing	  transduction	  and	  induction	  
	  
Next, the optimal settings for the highest transduction and induction efficiency were 
established. For this, we plated 50’000 T269 cells on Poly-Ornithin/Laminin coated 
glass coverslips in a 24-well culture plate and infected them with 10, 50, 100 and 200 
IFU/cell. In parallel, we tested different concentrations of Doxycycline in the culture 
medium, ranging from 1 to 10 µg/ml (1/1000 to 1/100 on Fig2A). Optimal and 
efficient transduction and induction were obtained when cells were infected with 100 
IFU/cell and exposed to 2 µg/ml (500x) Doxycycline (Fig2A). 
1.4 Establishment	  of	  sphere	  cultures	  and	  assays	  
	  
Culture conditions vary between different types of cell lines and one has to adapt the 
frequency of passaging, the density of seeded cells, the need for supplementation of 
conditioned medium, the optimal CO2/O2 concentrations and the temperature. Already 
at the morphological level, S24 and T269 cells differed significantly. S24 showed a 
more rounded shape whereas T269 were more elongated when grown as a monolayer 
(Fig2 B and C, respectively). The difference in sphere formation capacity of S24 and 
T269 tumor-initiating cells was noticeable since in our culture conditions S24 cells 
were more proliferative. In order to test the difference in proliferation and sphere 
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formation capacity, different cell densities were plated and the formation of spheres 
bigger than 50µm was analyzed after four days. T269 cells formed 15.78 ± 3.31 
spheres at a minimal density of 10 cell/µl whereas S24 cells were faster and only 
needed 1 cell/µl in order to generate 14.50 ± 1.83 spheres (Fig2 D and E, 
respectively). We concluded that T269 cells needed a higher cell density for 
proliferation and sphere formation. Therefore, for all sphere formation assays, we set 
the optimal cell density at 7 cells/µl for S24 cells and 10 cells/µl for T269. 
	  
Figure 2 Establishing optimal settings for lentiviral transfection and induction in a sphere formation 
assay. A T269 showed high transduction efficiency with 200 and 100 IU/cell as observed following 
Doxycycline administration at 2 µg/ml (1/500). S24 cells show a less elongated morphology (B) 
compared with T269 cells (C). D Four days after seeding 10 cells/µl, T269 generated 15 spheres 
whereas S24 formed the same number of spheres after seeding 1 cell/µl (E) Scale bar = 200µm 
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2.	  Translation	  to	  in	  vivo	  
	  
2.1	  Choice	  of	  the	  cells	  
	  
Glioblastoma multiforme is a highly aggressive type of brain tumor and is known to 
grow diffusely throughout the brain (Claes et al. 2007, CBTRUS statistical report 
2006). To choose one of the cell lines for the in vivo assay we compared the migratory 
capacities of both T269 and S24 cells with a 3D matrigel invasion assay at 24, 48 and 
72h and found that T269 were more invasive compared with S24 cells (Fig3 A-C). In 
parallel, we tested whether overexpression of dnE47 influenced invasion using the 
same assay, but no significant effect was detected except at 72h post-induction for 
T269 cells (Fig3 C-E). We chose T269 tumor-initiating cells for further in vivo 
experiments. 
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Figure 3 T269 tumor-initiating cells show a more invasive behavior than S24 cells in control RFP 
conditions and when comparing dnE47 overexpression. Upon Doxycycline induction, no significant 
difference in the invaded area was detected between T269 and S24 cells neither when RFP (A) nor 
dnE47 (B) were overexpressed. The representative close-up pictures show invading tumor-initiating 
cells migrating out of spheres upon RFP or dnE47 induction (C). DnE47 overexpression does not 
influence invasion of S24 cells (D) and has little influence on the invasive properties of T269 cells (E). 
Scale bar = 250 µm 
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2.2	  Tumor	  evolution	  and	  tracking	  
	  
For visualization of the transplanted cells, T269 cells were transduced with a 
lentivirus that constitutively expresses GFP. Following transduction, cells were FAC-
sorted in order to reach a pure GFP positive culture. After co-transduction with either 
the RFP or the dnE47 lentivirus, cells were transplanted into the right striatum of 
immunedeficient mice (2 mm lateral, 1 mm anterior from Bregma, -3 mm 
dorsoventral). Doxycycline was administered at 30d post-transplantation; 3 animals 
per group were sacrificed two weeks upon induction and 7 animals were kept alive 
until the onset of clinical symptoms (such as motor impairments, lack of grooming 
and explorative behavior and pain symptoms) in order to evaluate the effects of 
dnE47 overexpression onto tumor formation and to generate a Kaplan-Meier survival 
curve (Fig4A, experimental design and Chapter 2 Fig6D). On histological sections 
collected at 30d and 44d after transplantation, we saw that the tumors had grown 
diffusely within all brain regions. GFP-positive cells appeared to migrate extensively 
along white matter tracts (Fig4B-C). At the time of onset of clinical symptoms (i.e. 
when the animals were sacrificed), the tumor was clearly visible in most brain areas 
(Fig4D). We then analyzed the percentage of GFP-human nuclear antigen (hNA) 
double positive cells by immunohistochemistry to confirm accurate detection of 
human grafted cells within murine tissue (Fig4E). Co-localization between hNA and 
GFP positive cells reached almost 100% in all the quantified regions: the 
subventricular zone (SVZ), the corpus callosum (CC) and the Fimbrae hippocampi 
(HFi) (Fig4F). 
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Figure 4 Evolution of T269-induced tumors in athymic mice. A Experimental design of the study in 
which expression of the transgene (i.e. RFP or dnE47-RFP) lentiviruses were induced 30 days after 
grafting and animals sacrificed either 14 days upon Doxycycline administration for histological 
analyses or when tumor-bearing mice showed clinical symptoms (i.e. Score 2). Grafted GFP positive 
cells were clearly visible 30 days after transplantation (B), and continued expanding at 44 days (C) and 
75 days (D). E Human nuclear antigen and GFP positive cells were detected in all regions of the brain 
and showed an almost 100% co-localization (F). B-D Scale bar = 1000µm, E’ Scale bar = 50µm, E’’ 
Scale bar = 10µm 
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2.3	  Induction	  efficiency	  in	  vivo	  
	  
Next, the induction efficiency for both RFP and dnE47 vectors was characterized by 
analyzing the percentage of GFP-RFP double positive cells in periventricular or 
parenchymal brain regions. In general, the RFP signal from both induced vectors was 
strong in regions close to the ventricles (SVZ, Corpus callosum, Fimbrae 
Hippocampi) whereas RFP expression was weaker and more heterogeneous in regions 
further away from ventricles such as the striatum and in the forebrain (Fig5A). The 
RFP control vector was induced in 98% ± 0.2 of the GFP positive cells near the 
ventricles and 92% ± 5.8 in regions further away. Regarding the dnE47 vector, close 
to the ventricles, 91% ± 0.4 of GFP+ cells were positive for RFP whereas 71% ± 6.6 
were positive further away (Fig5B). Overall, the induction efficiency in GFP+ cells 
was higher for the RFP control vector (95% ± 2.8) than for dnE47RFP (81% ± 5.2) 
(Fig5C). 
	  
Figure 5 Induction of RFP and dnE47RFP upon Doxycycline treatment is highly efficient in vivo. A 
Representative pictures of GFP positive transplanted cells (left) and Doxycycline induced RFP signal. 
B Highest induction efficiency was quantified near the ventricular system whereas it was lower and 
more heterogeneous away from the ventricles. C pSIN_RFP showed higher and more stable induction 
overall. Scale bar = 1000µm 
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2.4	  Fluorescence	  intensity-­‐based	  cell	  distribution	  analysis	  on	  
histological	  sections	  
	  
Tumor cells migrated over long distances following engraftment, rendering their 
quantification particularly challenging. In order to characterize the growth of the 
tumors in future studies, we tested three different methods in order to analyze the 
distribution and migratory capacities of transplanted cells.  
The first approach consisted in detecting the distribution of GFP+ cells on a 
“heatmap” representing their localization in a color-coded manner. This approach 
includes generating a plot profile of the total grey value distribution over the whole 
section. To start with, mosaic scans of each section were acquired on a fluorescence 
microscope equipped with a motorized stage at 10x magnification. The images were 
converted to a 16bit picture with the software ImageJ.  Using the plug-in “heatmap 
histogram” (created by Dr. Samuel Péan), a heatmap view of the section is created 
showing the density distribution of the GFP signal which reflects the 
distribution/location of the tumor cells throughout the section (Fig6 A-E). For a more 
quantitative approach, one can create a plot profile showing the distribution of the 
signal detected as grey values from the left to the right side of the section (Fig6 F). To 
allow the comparison of different sections, the mosaic scans must be generated using 
the same settings (exposure time, gain). For example, one could focus on 3-4 sections 
of a specific anatomical region and the differences in the plot profiles between groups 
tested. For future follow-up studies, sections from the Fimbriae Hippocampi could be 
analyzed and the plot profile differences between the RFP control group and the 
dnE47 overexpression group compared.  
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Figure 6 Section heatmaps showing the density distribution of GFP positive cells. A-E Heatmaps 
(left picture) created from mosaic sections (center picture). The sections from the Mouse Brain Atlas 
(right picture) help illustrating the anatomical location of the transplanted cells. F Example of a plot 
profile of section D showing that the cells are mainly located in the right hemisphere, i.e. the side of the 
injection. Scale bar = 1000µm  
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2.5	  A	  stereological	  approach	  for	  Fluorescent	  Euclidean	  Vector	  
Analysis	  (FEVA)	  
	  
We developed a quantitative approach based on stereology for precise and unbiased 
counting of spatially distributed cells. 30µm-thick sections were cut, and every 12th 
serial section was collected. To determine the total area to be analyzed, we used the 
Cavalieri estimator to generate estimates of sectional surface and volume. A point-
grid (x- and y-point distances: 500 micrometers) was placed on each section, and each 
point falling on the tissue was counted. A total of 27 sections was analyzed, resulting 
in a point count of 4135. Based on the point count, the area to be sampled was 
estimated to be 1’033’750’000 µm2 (Table1). The coefficient of error (CE) of this 
estimate was calculated based on the Gundersen-Jensen estimator (G-J) (Gundersen et 
al. 1999). Part of the G-J CE estimator is the smoothness factor m, m=1 representing a 
smooth and m=0 a jagged distribution (Slomianka & West 2005). In our case, the 
counts were distributed evenly and therefore a smoothness factor of 1 was considered 
(Fig7A). Analysis of every section resulted in a G-J CE of 0.006, i.e. the standard 
deviation of repeated measurement would amount to only 0.6% of the mean of the 
repeated measurement. To determine how the section-sampling interval influenced 
our G-J CE estimates, we compared the CE for all sections (i.e. 0.006) with that of 
every second section. Noticeably, analysis of every second section also gave a 
precision of 0.006.  
Next, to determine the distribution of our sampling sites on the sections, we calculated 
the size of the sampling grid for the optical fractionator considering a number of 400 
sampling sites in the total area to be analyzed: square root of (total area/400). This 
would give us a spacing of 1.6mm, but we decided to use systematically random 
sampled sites every 1mm providing a total of 1112 sampling sites. The counting 
frame size was set to 90x110 µm (Table1). Both hemispheres were considered 
separately and the number of GFP+ cells co-localizing with DAPI+ nuclei were 
counted at 63x magnification. In total, 331 cells were counted and the total number of 
cells within the brain was calculated using the optical fractionator method: 
𝑁 = 1𝑠𝑠𝑓 ∗ 1𝑎𝑠𝑓 ∗ 1ℎ𝑠𝑓 ∗ 𝑄 
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In our example, the section sampling fraction (ssf) is defined by every 12th section 
being analyzed, i.e ssf = 1/12. The area sampling fraction (asf) is the counting frame 
area divided by the sampling grid area, i.e asf = (90*110)/(1000*1000) = 0.0099. We 
counted cells through the whole section thickness, which gives us a height sampling 
fraction (hsf) of 1 since hsf is the height of each fractionator sample divided by the 
average section thickness, i.e. hsf = 30/30 = 1. Q stands for the total number of 
counted cells, i.e. 331 for the entire brain, 183 for the ipsilateral hemisphere and 143 
for the contralateral hemisphere. Thus, 30 days after injection of 100’000 cells in the 
right striatum, the cells proliferated to reach a total number of 401’212 cells; 221’818 
cells remained in the ipsilateral hemisphere whereas 173’333 cells migrated 
contralaterally (see also Table1): 
𝑁!"! = 1112 ∗ 10.0099 ∗ 1 ∗ 331 = 401′212 𝑁!"#! = 1112 ∗ 10.0099 ∗ 1 ∗ 183 = 221′818 𝑁!"#$%& = 1112 ∗ 10.0099 ∗ 1 ∗ 143 = 173′333 
Since we used the Stereo Investigator software coupled to an x-y-z motorized stage, 
each counted cell is located in a Euclidean space and has its own x-y-z coordinates 
(Fig7B). Based on them, and knowing the coordinates of the injection site, it is 
therefore possible to calculate the minimal migration distance of grafted cells as the 
norm 𝑎   of a Euclidean vector: 𝑎 = 𝑥! + 𝑦! + 𝑧!  
Based on bins of 500um, the frequency distribution of our fluorescent vectors showed 
a bimodal distribution when considering vectors within the whole brain as well as for 
the ipsilateral hemisphere (Fig7C-E).   
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Table1 
 
Mean 
cells 
Total 
count area 
(µm2) 
Mean CE 
(m=1) 
Sampling 
grid size 
(µm) 
Counting 
frame size 
(µm) 
Sections 
assessed 
Cells 
counted 
Whole brain 401‘212 
1033750000 
0.06 1000 
x 
1000 
90x110 27 
331 
Ipsilateral 221‘818 0.07 183 
Contralateral 173‘333 0.08 143 
 
 
 
Figure 7 Stereological Fluorescent Euclidean Vector Analysis. The distribution of Cavalieri points 
over analyzed section shows a smoothness factor of 1 (m=1) (A). 3D representation of analyzed 
sections. Contours from the ipsilateral hemisphere are in yellow, contours from the contralateral 
hemisphere in red. Black triangles represent counted GFP+ cells and the green asterisk the injection site 
(B). The distribution of vector frequency within the entire brain (C), the ipsilateral (D) as well as the 
contralateral hemisphere (E) shows a bimodal distribution. Distances are given in µm from the 
injection site.  
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2.6	  Automated	  software-­‐based	  number	  and	  distribution	  analysis	  
	  
The third approach for analyzing the number and distribution of GFP+ glioma-
initiating cells in the brain was based on an automated acquisition of the sections and 
analyses of the cells. Here, images of 25 30µm-thick brain sections were acquired on 
a Zeiss Mirax Midi Slide Scanner with the same exposure and stitching settings for 
each slide. Then, the number of GFP+ cells was counted automatically with the 
Software HistoQuant Module (3DHISTECH, Budapest, Hungary), adapting the 
settings for each slide and including cells having a perimeter ranging between 35 and 
1000 µm2. A total of 21’354 cells were counted, which gives an approximation of 
256’248 cells in total, considering that every 12th section was serially collected. Then, 
we analyzed the distribution of grafted cells with the software Imaris 7.5 (Bitplane 
AG, Zurich, Switzerland). First, a stack containing each section was created with the 
free software ImageJ and the sections aligned using the StackReg plugin (Fig8A) 
(Thévenaz et al. 1998; Schneider et al. 2012). As a reference for spatial positions, the 
injection site was labeled in red on the relevant section (Fig8B). The injection site 
was quantified as a surface and GFP+ cells as spots in a 3D space in order to calculate 
their xyz position (Fig8B). A total number of 12’073 cells were detected in the 
ipsilateral hemisphere whereas 6’407 cells were positioned in the contralateral side, 
which gave a total of 18’480 cells in the whole brain. Since we analyzed every 12th 
section, 221’760 cells were detected 30 days after transplantation. Next, we calculated 
the migration distance of each grafted cell from the injection site using the same 
vector norm approach as mentioned above (see Stereological FEVA). Here again, 
based on bins of 500µm, the frequency distribution of vector norms showed a slight 
bi-modal shape (Fig9C-D). 
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Figure 8 3D views generated with the software Bitplane Imaris. The 3D reconstruction of a stack 
shows the spatial positioning of transplanted cells 30d after injection (A). The green spots detect GFP+ 
cells and the red arrow points at the injection site (B). Scale bar = 2000 µm. 
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Figure 9 An automated software-based quantification of grafted GFP positive cells shows a bi-modal 
distribution. The vector norms of transplanted cells located in the ipsilateral (A), contralateral (B) and 
whole brain (C) show a bi-modal distribution. 
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Discussion	  and	  outlook	  
 
In this chapter, we presented the development and establishment of all necessary tools 
and experimental methods for assessing the effects of (b)HLH transcriptional network 
disruption in tumors both in vitro and in vivo. We first cloned and generated high-titer 
batches of inducible lentiviruses. We then established the optimal conditions for 
culturing tumor-initiating cell sphere and finally, we translated our findings in vivo by 
inducing tumors in immunosuppressed mice and developed methods to characterize 
the growth of tumors on serial histological sections. 
Tumor-initiating cells isolated from patient biopsies provide new tools to test the 
efficiency of potential drugs or other therapeutic approaches (Tentler et al. 2012; 
Schonberg et al. 2013). However, human brain tumors show high heterogeneity in 
terms of molecular profile and physiology and this is also the case for patient-derived 
tumor initiating cells (Tang 2012; Schonberg et al. 2013). It is therefore not surprising 
that S24 and T269 tumor-initiating cells show differences in their gene expression 
levels, their proliferative behavior and their invasion capacity although they both were 
derived from glioblastoma multiforme biopsies. For our purposes, we selected the 
T269 cell line as they showed higher expression levels of (b)HLH transcription 
factors and mirrored more closely the highly invasive behavior of glioblastoma 
multiforme tumors (Claes et al. 2007). Their different molecular profiles, proliferation 
rates and invasive behavior support the concept that cancer stem cells are highly 
heterogeneous, can lead to different prognoses for patients and therefore should be 
targeted in a multimodal approach (Tang 2012; Schonberg et al. 2013).  
Glioblastoma multiforme grow diffusely throughout the brain and grafting of T269 
tumor-initiating cells phenocopied this behavior. Since the tumors were not compact 
and local, we established new methods for analyzing their number and distribution. 
The generation of heatmaps appeared to be particularly suited for evaluating whether 
tumor cells migrate to the hemi-brain contralateral to the injection site. This method is 
an innovative way of presenting section pictures as a heatmap and gives a fast 
overview on the cell distribution within sections. However, heatmap histograms 
cannot be used for exact quantitative analyses but merely for illustrative purposes as 
they only show in which anatomical regions the cells are mostly located. 
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A quantitatively more accurate method is an automated quantification using imaging 
software such as Histoquant, ImageJ and Imaris. Here, it is necessary to set all 
acquisition and quantification parameters and settings as precisely and reliably as 
possible in order to avoid false-positive or false-negative results. Nevertheless, the 
most exact approach, relying on statistic-based methods, is a stereological 
quantification as both automated software-based methods underestimated the total 
number of GFP+ cells. In order to analyze a heterogeneous distribution of cell 
population, a methodological approach that does not imply counting each cell on each 
section is required. Stereology fulfills these conditions as it provides a quick, non-
costly statistically relevant tool for a large heterogeneously distributed cell 
population. To conclude, heatmaps can be useful for illustration and the number and 
distribution of grafted cells can be quantified in an automated way if no stereology 
software is available. Otherwise, stereology-based analyses provide the most accurate 
results that reflect the actual number and distribution of grafted cells within the brain. 
As an outlook for future studies, these histological and morphological methods will 
lead to more detailed investigations of the effects of dnE47 overexpression in vivo. 
For instance, alterations in proliferation and apoptosis will be analyzed on histological 
sections upon two weeks of Doxycycline administration with Ki67, Casp3a, TdT-
mediated dUTP-biotin nick end labeling (TUNEL) or intravenously injected 
fluorescent Annexin V (Bahmani et al. 2011; Pernet et al. 2012). For in vivo 
proliferation analysis, a possibility will also be to give the animals pulses of the 
thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) in order to label proliferating 
cells. As a non-invasive approach in order to assess tumor growth, it would be 
possible to monitor tumor evolution with bioluminescence imaging (BLI), a technique 
based on luciferase emitting grafts, or with far-red luminescence imaging (Szentirmai 
et al. 2006; Wu et al. 2009; Sun et al. 2010; Deliolanis et al. 2011). Alternatively, in 
order to assess the invasive behavior of tumor-initiating cells, an additional approach 
might be to seed cells or spheres onto organotypic slice cultures and characterize their 
invasive properties in an ex vivo system (Ohnishi et al. 1998; Jenei et al. 2011). The 
combination of ex vivo histological and in vivo non-invasive imaging analyses will 
enable a detailed assessment of tumor growth and histology upon dnE47 
overexpression. Furthermore, these tools and methods could also be translated to 
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other types of cancers and their tumor-initiating stem cells, giving deeper insights 
about the similarities in regulatory pathways between different cancer types. 
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Human	  tumor-­‐initiating	  cell	  transplantation	  in	  Drosophila	  Melanogaster	  
	  
Abstract	  
 
In order to confirm results from our in vitro experiments, we sought for an innovative 
approach as an alternative to classical murine xenograft models. Drosophila 
melanogaster is well-established genetic tool and model for cancer research. We 
transplanted human tumor-initiating cells into the abdomen of fruit flies and 
monitored the evolution of grafted cells over two weeks. GFP positive human cells 
were detected up to 4 days after transplantation with a clear loss of grafted cells after 
48h. We concluded that this approach was not feasible and chose to use athymic mice 
instead.  
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Introduction	  
	  
The primary goal of life science research is to understand the basic physiological, 
metabolic and structural mechanisms and functions in the context of healthy and 
diseased organisms. However, ultimately, research aims at applying this knowledge to 
the development of diagnostic and therapeutic tools for humans. Since decades, 
scientists have been seeking the answer to how does a disease arise, how does it 
develop and how can it be counteracted. In cancer as in any other field of disease 
research, one has to start with simple tools such as lower model organisms, 
immortalized cell lines or primary cells or computational models. As a next step, 
promising in vitro results need to be confirmed in a less artificial and more complex 
system in order to first, confirm and assess the relevance of the findings and second, 
to take a step closer to the development of novel therapeutic tools for humans in 
clinical trials.  
 
At this transition point between in vitro and in vivo, classical procedures consist of 
combining human orthotopic or heterotopic grafts, with a murine host, which 
presupposes working with an immunodeficient animal. Two models are widely used: 
the athymic so-called nude mice that lack T cells and severe combined 
immundeficient (SCID) mice that lack both T and B cells. Nude mice lack their 
thymus and cannot produce any T cells because of a mutation in the FOXN1 gene 
whereas SCID mice genome harbors a recessive mutation in the gene prkdc that 
impairs the maturation of their humoral and cellular immune system (Flanagan 1966; 
Bosma et al. 1983; Mecklenburg et al. 2001). More receptive host animals were then 
developed by combining the SCID mutation with the non-obese diabetic (NOD) 
model, resulting in a more receptive host for transplantations (Greiner et al. 1995; 
Christianson et al. 1997). Absence of immunity enables to transplant human grafts 
and characterize the formation and evolution of human tumors within a murine host.  
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However, when one needs to translate their findings from in vitro to in vivo, the 
ethical question of balance of interest arises where scientists have to consider whether 
the outcome or the significance of the experiment is worth the life or the pain of an 
animal. In Switzerland, animal experimentations are tightly regulated by the 
Confederation and the cantons that allow researchers to work with animals based on a 
license system (http://www.bvet.admin.ch/themen/tierschutz). For each license, a 
scientist needs to think about the necessity of the experiment, the wellbeing of the 
animals and how to minimize the number of animals. This concept is also known as 
the 3 Rs that are: refine, reduce and replace (http://www.forschung3r.ch). And so in 
this study, in an attempt to respect the 3Rs and to develop a novel tool, we challenged 
the fruit fly Drosophila Melanogaster with a human tumor-initiating cells xenograft. 
Fruit flies are established genetic models in which the homology to human genes 
enables to conduct basic research with the goal to extrapolate findings to the 
mammalian system (Gont et al. 2013). They have been used for genetical analyses for 
a century and their genome has been fully sequenced (Adams et al. 2000). 
Furthermore, their short generation time, easy handling, low-cost maintenance as well 
as the inexistence of restrictions in the number of flies used in experimentations, 
permits to conduct efficient large-scale studies. In the context of cancer research, 
Drosophila flies have recently been established as GBM and tumor models in which 
overexpression of EGFR, PI3K, PDGFR or RAS homologs lead to tumor formation 
(Witte et al. 2009; R. D. Read et al. 2009; Read 2011; Gonzalez 2013). Similarly to 
mammalian models, tumor generation and characterization via transplantation have 
also been developed and used in flies (Caussinus & Gonzalez 2005; Berger et al. 
2012). Here, overexpression or knockdown of genes prior engraftment influenced the 
ability of the graft to form tumors within the host. Furthermore, after abdominal 
transplantation, the migration of tumor cells to ovaries or the eyes gives an insight on 
their ability to form metastases. One can not only manipulate the cells prior grafting 
but also the host itself, giving rise to infinite possibilities of experimentations.  
 
In this study, the goal of our approach was to first, test the possibility to transplant 
human cells into Drosophila Melanogaster and second, to overexpress dnE47 in the 
grafted cells and assess its effects onto tumor formation. 
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Material	  and	  Methods	  
 
Cell lines and culture  
Both S24 and T269 human tumor-initiating cells were used in this experiment. 
Results and figures are described and shown for T269 cells only. Similar results were 
obtained with S24 cells. Cells were cultured in DMEM:F12 (Gibco) supplemented 
with 2% B-27 minus Vitamin A (Gibco), 1% antibiotic-antimycotic 100x (Gibco), 
human leukemia inhibitory factor 20ng/ml (Millipore, Merck, Billerica, MA), Heparin 
5ug/ml (STEMCELL Technologies, France), recombinant human fibroblast growth 
factor 20ng/ml (Peprotech, Germany) and epidermal growth factor 20ng/ml. Cells 
were maintained at clonal densities (10 cells/µl) in T75 culture flasks (TPP) at 
37°C/5% CO2 and passaged once a week using Accutase (Chemie Brunschwig AG, 
Switzerland) for dissociation. 
 
Drosophila line 
Female w1118 flies were maintained on standard cornmeal-yeast agar medium at 250C. 
3-4 days-old host flies were used for all transplantation procedures. Groups of 60 flies 
per condition were made. 
 
Abdominal transplantation 
Transplantations were performed as previously described (Caussinus & Gonzalez 
2005). Briefly, injection needles were manufactured by pulling them to a diameter of 
around 90µm, cut and sharpened. About 1mm away from the needle tip, a constriction 
was inserted with a microforge. Then, the needle was inserted through a holder into a 
piece of silicon tubing with a mouthpiece on the other end. The cells or spheres were 
washed, resuspended in sterile PBS 1X and placed in small drops of PBS on a 
microscope slide. Before starting transplantations, host flies were anesthetized with 
CO2 and stuck on an ice-cold plate, ventral side up, with double-sided sticky tape. 
Cells or spheres were aspirated within the tip of the needle and injected tangentially in 
the mid-ventral abdomen. Post-recovery from anesthesia, flies were let to recover and 
kept under standard conditions at 250C and 290C.	   
	   91	  
	  
Figure 1 Schematic overview of abdominal transplantation procedure (adapted from Gonzalez et al. 
2007) 
 
Microscopy 
Pictures were taken with a Leica MZFLIII fluorescence microscope (Leica 
Microsystems, Mannheim, Germany) at 2.5x and 3.5x fold magnification. 
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Results	  	  
	  
As an alternative to the use of nude mice, we attempted to develop a novel tumor 
xenograft model in flies. We transplanted T269GFP+ and S24GFP+ tumor-initiating 
cells in the abdomen of female wild-type Drosophila flies. Either dissociated cells or 
entire spheres were grafted and the GFP signal was monitored on the day of the 
transplantation, at 24h, 48h, 4d, 7d and 14d after injection. After transplantation, one 
group of flies per condition was maintained at 250C and one at 290C. At 24h after 
injection, tumor cells were seen to spread in the whole body of the flies, with GFP+ 
cells detected in the thorax as well as the eyes. Their presence could be detected up to 
4d (Fig2). However, a net loss was evidenced after 48h and no cells (neither 
dissociated nor entire spheres) could be detected 7 days and 14 days after the 
transplantation suggesting that the flies had rejected the human graft. Both T269 and 
S24 cells showed similar results regarding the loss of cells as well as the death of 
animals being quicker when the flies were kept at 290C. The failure of grafted cells to 
develop into tumors lead us to the conclusions that the immune system of Drosophila 
Melanogaster must have reacted to the xenograft and get rid of it. Therefore, we 
concluded that a more common approach with immunodeficient mice was the 
appropriate way to translate our findings in vivo. 
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Figure 2 T269 tumor-initiating cells transplanted in the abdomen of Drosophila Melanogaster flies. 
Transplanted cells transduced with a constitutive GFP lentivirus can be detected in the abdomen from 
the day of injection and up to 4 days. 1 week and 2 weeks later, only the injection scar is seen (white 
star).  
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Discussion	  
	  
In this study, human tumor-initiating cells were transplanted into the abdomen of 
Drosophila Melanogaster. The cells migrated up to thoracic levels and to the eyes but 
could only be detected until 4d after injection. The fact that the invertebrate 
environment seems deleterious to a human graft stands in sharp contrast with the high 
homology between the fruit fly and the human genomes (Reiter et al. 2001; Pandey & 
Nichols 2011). More interestingly, the bHLH transcriptional network this whole 
project is focusing on is also present in D. Melanogaster. For example, the fly gene 
Daughterless is the homolog of the human E2A gene that codes for E47 (Quong et al. 
1993). Homologs of ID proteins have also been characterized: the gene 
extramacrochaetae (emc) codes for a protein lacking its DNA binding domain and 
involved in development and the formation of the midgut (Ellis et al. 1990; Ellis 
1994). This high homology between the genomes of D. Melanogaster and Homo 
sapiens would have presupposed better survival chances for a human xenograft in 
fruit flies. It would however be interesting to test whether a similar dominant-negative 
approach as shown with dnE47 could be translated to Daughterless since this gene is 
know to be involved in the regulation of cell cycle in Drosophila and its C. elegans 
homolog HLH-2 in cell invasion (Sukhanova et al. 2007; Sukhanova & Du 2008; 
Schindler & Sherwood 2011). 
 
Our attempt to develop an alternative approach to classical immunodeficient models 
had to face the fact that transplanted GFP positive cells could not be detected one 
week after engraftment anymore. This argues for the presence of an immune system 
in Drosophila flies. Indeed, fruit flies can resist to different pathogens, such as 
C.Albicans, thanks to an innate immune system, present in the systemic circulation 
(Boman et al. 1972; Lemaitre et al. 1996). In order to circumvent this system and give 
the chance to a human xenograft to survive in this organism, one possibility would be 
to use genetically modified Drosophila, similar to immunodeficient mice. 
Immunosuppressed mutants have already been described such as flies that lack a 
functional Toll receptor or such as near Black cell mutants (Corbo & Levine 1996; 
Alarco et al. 2004). The Toll-receptor pathway controls the production of an 
antifungal peptide, drosomycin in response to infections whereas a mutation near the 
Black cell gene impairs the response of immunity genes such as cecropins and 
	   95	  
diphterins (Kylsten et al. 1990; Wicker et al. 1990). Mutations in these genes impair 
therefore a response from the immune system after infection and might also avoid a 
rejection of a xenograft. 
 
Next to immunodeficient D. melanogaster, an alternative method would be to use 
another well-established genetic model such as Danio rerio (zebrafish). First, this 
organism has the similar advantages to Drosophila Melanogaster regarding the 
maintenance and care: low costs, short breeding time, established genetic tools. 
Second, being a vertebrate makes it therefore phylogenetically closer to humans. In 
fact, zebrafishes have been widely used as models to genetically dissect diverse 
human diseases, including cancer (Goldsmith & Jobin 2012). In the context of colon 
cancer, the RAS-MAPK pathway has been shown to promote tumor formation in 
zebrafish similar to humans (Hruban et al. 1993; Park et al. 2008). Furthermore, as in 
murine and fruit fly models, xenograft transplantation assays have been developed 
and established complemented with imaging methods to follow the expansion of the 
disease (Taylor & Zon 2009; Ignatius & Langenau 2011; Cao et al. 2013). 
 
As a conclusion, both immunosuppressed Drosophila flies and xenograft 
transplantations in zebrafish underline the potential of alternative methods to 
canonical mammalian tumor models and should be considered as valid models for 
cancer research as well. Not only will they reveal new hits for the development of 
new therapeutic approaches but will also give the possibility to screen for drugs and 
treatments. 
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Chapter	  V	  
	  	  	  
Discussion	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Discussion	  
	  
Glioma cells are characterized by their highly proliferative behavior, their invasive 
properties and their angiogenic capacities (Furnari et al. 2007; Westphal & Lamszus 
2011). The transcription factor family of helix-loop-helix (HLH) and basic HLH 
(bHLH) proteins was shown to be involved in all of these features (Perk et al. 2005; 
Aguirre-Cruz et al. 2004; Somasundaram et al. 2005). Originally, this study was 
designed to use E proteins as an anti-glioma tool to 1) counteract pro-proliferative 
effects of ID proteins and 2) transactivate proneural proteins in order to promote 
terminal differentiation. However, this strategy appeared to be efficient in a 
subpopulation of glioma cells that expressed low level of proneural proteins only, 
suggesting instead that proneural proteins transactivation participate to 
tumorogenesis. Indeed, engineering a dominant-negative E protein that concomitantly 
sequestered both ID and bHLH proteins in the cytoplasm, hence impairing their 
transcriptional activity, proved to be effective more consistently. It should however be 
noted that although overexpression of dnE47 consistently led to proliferation 
impairments and induced apoptosis in both immortalized cell lines and patient-
derived tumor-initiating cell lines, eradication of the tumor cells was neither reached 
in vitro nor in vivo. This observation suggests the presence and/or development of 
resistance or escape mechanisms in the targeted cells and raises several issues, which 
will be discussed here.  
 
Class I bHLH proteins consists of four E proteins (E47, E12, E2-2 and HEB) which 
have been shown to be interchangeable regarding their ability to bind ID proteins 
(Massari & Murre 2000; Teachenor et al. 2012). This suggests that overexpression of 
dnE47 alone might not be sufficient enough to disrupt the whole transcriptional 
network, as it needs to “compete” with all endogenous E-proteins that are expressed 
at a given time in glioma cells. It is also possible that different E proteins may have 
slightly different targets. Supporting this idea, E47 and E12 have different functions 
in the maturation of B cells, suggesting differential transcriptional functions for each 
E protein (Beck et al. 2009).  
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It should also be mentioned that in addition to their partner roles for bHLH proteins in 
promoting their transcriptional activity, E proteins might also directly participate to 
tumor homeostasis. Some of these functions might be mediated by the formation of E-
proteins homodimers. For example, it has been shown that E47 is involved in 
promoting proliferation, epithelial to mesenchymal transition (EMT) and apoptosis in 
cancer cells (Engel & Murre 1999a; Peverali et al. 1994; Trabosh et al. 2009; Perez-
Moreno et al. 2001). Besides E47, E2-2 was also shown to regulate epithelial-
mesenchymal transition (EMT) via E-cadherin repression in vitro (Sobrado et al. 
2009). Dominant negative E proteins overexpression is likely to disrupt formation of 
functional homo and/or heterodimers, by sequestering other Class I proteins in the cell 
cytoplasm as well, disrupting thereby their oncogenic role (Massari & Murre 2000; 
Murre 2005). In conclusion, the incomplete anti-glioma effects of dnE47 
overexpression might be due to a compensatory mechanism from the other E proteins 
or to the pro-tumor properties of E47.  
 
Post-translational modifications such as phosphorylation greatly influence protein 
functions and could affect the anti-glioma effects after dnE47 overexpression. In 
neural stem cells of the embryonic spinal cord for example, Olig2 has a pro-
proliferative function when phosphorylated whereas in its unphosphorylated state, it 
supports oligodendrocytes differentiation (Li et al. 2011). Similarly, E47 is subjected 
to post-translational phosphorylation, which influences its stability and transcriptional 
activity in skeletal myoblasts and B-lymphocytes (Sloan et al. 1996; Page et al. 2004). 
The question remains whether phosphorylation of E proteins occurs in cancer cells 
and thereby alters their binding properties and functions, for example in apoptosis 
and/or E-cadherin mediated EMT. Post-translational modifications of both HLH and 
bHLH proteins could influence the interplay between E and ID proteins which 
regulates proliferation and differentiation during development as well as in the 
diseased brain (Massari & Murre 2000; Jones 2004). Supporting this idea, 
phosphorylation by cyclin-dependent kinase 2 (cdk2) of ID proteins modulates their 
function in cell cycle progression as well as their binding abilities (Deed et al. 1997; 
Hara et al. 1997). In general, aberrant tyrosine phosphorylation through deregulated 
protein-tyrosine kinase and phosphatase signaling is a hallmark of many cancers 
(Hunter 1998; Blume-Jensen & Hunter 2001).  Hence, it would be interesting to 
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investigate whether phosphorylation of dnE47 would perturb or enhance its anti-
glioma effects. 
 
Besides phosphorylation, epigenetic mechanisms modify proteins expression and/or 
activity at the post-translational level and are known to interplay with the HLH/bHLH 
network. E proteins were shown to interplay with epigenetic modulators such as 
microRNAs. For example, E47 up-regulates mir-495 in breast cancer stem cells and 
induces hypoxia resistance and oncogenesis (Hwang-Verslues et al. 2011). 
Furthermore, E2A proteins are able to recruit a histone acetyltransferase in 
nonlymphoid cells in vitro (Sakamoto et al. 2012). Using the protein-interaction 
software STRING (STRING 9.05, http://www.string-db.org/), E2A was shown to 
interact with the histone deacetylase 2 (HDAC2) suggesting that E proteins are 
involved in the initiation of epigenetic modifications of the genome. Regarding ID 
proteins, epigenetic silencing of ID4 has been reported in liver cancer and in 
glioblastoma patients (Sharma et al. 2012; Martini et al. 2013). Since both E and ID 
proteins interact with epigenetic mechanisms, dnE47 overexpression might impair 
these post-translational modifications. This still needs to be further investigated in 
order to better understand the relations between the HLH/bHLH network and 
epigenetic modulations. 
 
ID proteins lack a DNA binding domain and act as negative regulators of E proteins 
(Ruzinova & Benezra 2003). ID proteins are highly expressed in tumor cells and 
mainly sustain their proliferative behavior as well as neo-angiogenesis within the 
tumor (Benezra et al. 2001; Perk et al. 2005). However, so far it is not clear whether 
each ID protein has unique functions and how their properties are regulated (Perk et 
al. 2005). ID proteins interact directly with many proteins involved in cell cycle 
regulation such as p16 or the retinoblastoma protein (Rb) for example (Ruzinova & 
Benezra 2003). E protein overexpression therefore is likely to impair interactions 
between ID proteins and their dimerization partners, thereby inhibiting the inhibitors 
(in other words ID proteins). What is known about ID functions and properties is 
mainly based on in vitro experiments and knockout studies and very few data about 
their endogenous in vivo properties is available. ID1 and ID3 were shown to interact 
with E26 transformation-specific (ETS) proteins and to be regulated by TGFbeta, 
VEGF and bone morphogenic protein 4 (BMP4) (Ying et al. 2003; Kang et al. 2003; 
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Kowanetz et al. 2004; Lyden et al. 2001; Ohtani et al. 2001). ID2 can interact with 
ETS proteins as well and is regulated by Rb and the MYC pathway (Nishimori et al. 
2002; Lasorella et al. 2000). There is less data on ID4 and its functions. In breast 
cancer cells, ID4 forms a feedback loop with the tumor suppressor breast cancer type 
1 susceptibility protein (BRCA1) and methylation of the ID promoter correlates with 
poor prognosis in the case of colorectal carcinomas (Welcsh et al. 2002; Umetani et 
al. 2004). These data therefore suggest a tumor suppressive role for ID4. However, 
which effects the deregulation of ID proteins has depends also on the cell type and it 
would not be surprising if different ID proteins had different functions depending on 
the type of cancer they are involved in (Perk et al. 2005). This high interplaying 
complexity between the (b)HLH network and other physiological pathways justifies a 
therapeutic approach aiming at targeting a network in its ensemble. Nevertheless, a 
possible drawback of this approach that needs to be further tested, is the possibility 
that network disruption may also hinder tumor suppressor pathways and may 
therefore lead to more aggressive tumors. 
 
Going along this line, numerous canonical cancer pathways were modulated after 
dnE47 overexpression, as illustrated by the qRT-PCR array results presented in 
Chapter 2. For instance, genes involved in proliferation, apoptosis, angiogenesis and 
metastasis were significantly up- or down-regulated following dnE47 overexpression. 
It will be interesting to investigate these changes in more details, e.g. to study their 
consequences for the cells behavior. Considering the broad spectrum of 
transcriptional modulations, it is reasonable to think that other canonical pathways 
such as Wnt or Notch signaling which play a role in tumor formation and 
maintenance, are also influenced by dnE47 overexpression. The Wnt pathway is 
implicated in both glioma and cancer stem cells homeostasis whereas Notch and its 
downstream targets are involved in the formation of medulloblastomas (Hatten & 
Roussel 2011; Gong & Huang 2012; Zhang et al. 2012). Further whole-genome 
transcriptional investigations will enable to understand to which extent (b)HLH 
network disruption affects tumor homeostasis. It will also give insights on the identity 
of which pathways (b)HLH proteins have the ability to interact with.  
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Despite numerous common pathways regulating their physiology, brain tumors are 
extremely various in their genomic and molecular profiles (Furnari et al. 2007; 
Westphal & Lamszus 2011; Verhaak et al. 2010; Phillips et al. 2006). This might be 
explained by two main reasons. First, studies revealed different cell types as possible 
cell-of-origin for tumor formation. Tumors can arise from diverse cycling cell 
populations such as neural progenitor and neural stem cells (Persson et al. 2010; Liu 
et al. 2011; Holland et al. 2000; Alcantara Llaguno et al. 2009; Cheng et al. 2009). 
Second, cells within a tumor are highly heterogeneous and show extremely dynamic 
abilities to adapt to changes of their microenvironment (Beier et al. 2011; Charles et 
al. 2011; Sottoriva et al. 2013). Consequently, inter- and intra-tumor heterogeneity 
challenges the development of therapeutic approaches specific for each tumor type 
and highlights the necessity to develop personalized treatments (Furnari et al. 2007; 
Schonberg et al. 2013; Chaudhry et al. 2013; Verhaak et al. 2010). A significant step 
in the direction of personalized therapy was the discovery that patients with MGMT 
methylation respond better to radiotherapy combined with TMZ treatment (Stupp et 
al. 2009). However, this is true only for glioblastoma but not for other types of brain 
tumors such as medulloblastoma or oligodendroglioma, which underlines again the 
need for development of tumor type-specific treatments (van den Bent et al. 2009; 
Faoro et al. 2011).  
 
Although we focused on the most aggressive type of brain tumors: glioblastoma 
multiforme, it should be noted that HLH and bHLH networks are also involved in 
numerous other cancer types. E, ID and bHLH transcription factors are also 
implicated in breast cancer, prostate cancer or leukemia (Perk et al. 2005; Ligon et al. 
2006; Desprez et al. 2003; Baer 1993; Perez-Moreno et al. 2001; Lee et al. 2011). 
Similarly to their functions in brain tumors, ID proteins are upregulated and sustain 
the  proliferative behavior of cancer cells in a wide range of tumors (Ruzinova & 
Benezra 2003; Perk et al. 2005). As similar pathways regulate tumor stem cells from 
different cancer types, it would be interesting to investigate the effects of dnE47 
overexpression in a wide range of cancers. Providing that dnE47 overexpression 
shows consistent effects in different cancer types, this would validate the 
manipulation of E proteins and (b)HLH network disruption as a therapeutic approach 
against global networks and would strengthen the possibility to consider transcription 
factors as potential therapeutic targets. 
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Targeting transcription factors as a therapeutic approach has been investigated 
recently with the aim to find central interactions on which formation, transformation 
and evolution of cancer cells and tumors rely (Ivanov et al. 2013; Yan & Higgins 
2013). The discovery of vital transcriptional pathway nodes relies on structure-based 
design studies and advanced screening methods (Ivanov et al. 2013). These 
approaches can be used to reveal effective protein-interaction modulators that proved 
to be efficient for cancer treatment. For example, small molecules inhibiting Signal 
Transducers and Activators of Transcription 3 (STAT3) impair its transcriptional 
activity and induce antitumor effects in breast cancer xenografts (Turkson et al. 2001; 
Siddiquee et al. 2007). Targeting the p53 tumor suppressor pathway with a Mouse 
double minute 2 homolog (MDM2) antagonist is in clinical trials for leukemia and 
lymphoma (Vassilev et al. 2004; Andreeff et al. 2003). In this project, we 
overexpressed a mutant E protein missing its nuclear localization signal as a protein-
protein inhibitor. Previous studies already took a similar approach using peptides for 
ID protein targeting. There, small peptides and aptamers were designed for binding 
ID proteins and impaired their dimerization interactions (Ciarapica et al. 2009; D S 
Mern et al. 2010b; Demissew S Mern et al. 2010). These studies showed that by 
narrowing down the peptides to their HLH domain, ID proteins are counteracted but 
the binding sites of these peptides for other bHLH dimerization partners are lost 
(Ciarapica et al. 2003). Hence, these approaches targeted only ID proteins without 
aiming at the whole HLH/bHLH network. Since we used a full-length protein in our 
approach, an interesting follow-up project could consist of trying to narrow down 
dnE47 to an inhibiting peptide that still has its binding functions and anti-glioma 
properties.  
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Considering the vast heterogeneity of brain tumors and numerous pathways involved 
in tumor homeostasis, several aspects will need to be investigated in more details. It 
will be crucial in the future to decipher the possibl multiple origins of tumors, to 
understand their regulatory pathways as well as to correlate their histology or 
molecular profiles with responses to therapy. These findings will be decisive in order 
to develop new multimodal and global therapeutic approaches as well as 
individualized therapies. For this, it will be necessary to bridge both bench work in 
neurobiology and bedside clinical trials with constant exchanges between both sides.  
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